

**EXCELSIOR MEDICAL CO., LTD.
AND SUBSIDIARIES**

CONSOLIDATED FINANCIAL STATEMENTS

**With Independent Auditors' Review Report
For the Three Months Ended March 31, 2026 and 2025**

**Address: 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235,
Taiwan, R.O.C.**

Telephone: (02)22251888

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1)Company History	8
(2)Financial Statements Authorization Date and Authorization Process	8
(3)New Standards, Amendments and Interpretations Adopted	8~9
(4)Summary of material accounting policies	10~12
(5)Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty	12
(6)Explanation of Significant Accounts	13~45
(7)Related Party Transactions	45~49
(8)Pledged Assets	50
(9)Significant Commitments and Contingencies	50
(10)Losses due to Major Disasters	50
(11)Subsequent Events	51
(12)Other	51
(13)Other disclosures	
(a) Information on significant transactions	51~54
(b) Information on investees	54~55
(c) Information on investment in mainland China	56~57
(14)Segment Information	57



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666
傳真 Fax + 886 2 8101 6667
網址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors Excelsior Medical Co., Ltd.:

Introduction

We have reviewed the accompanying consolidated balance sheets of Excelsior Medical Co., Ltd. and its subsidiaries as of March 31, 2026 and 2025, and the consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2026 and 2025, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As stated in Note (4)(b), the consolidated financial statements included the financial statements of certain non-significant subsidiaries, which were not reviewed by independent auditors. These financial statements reflect total assets amounting to \$999,218 thousand and \$841,710 thousand, constituting 5.13% and 4.49% of consolidated total assets as of March 31, 2026 and 2025, respectively, total liabilities amounting to \$200,619 thousand and \$226,998 thousand, constituting 2.71% and 2.87% of consolidated total liabilities as of March 31, 2026 and 2025, respectively, and total comprehensive (loss) income amounting to gains \$20,063 thousand and gains \$9,179 thousand, constituting 7.46% and 3.61% of consolidated total comprehensive (loss) income for the three months ended March 31, 2026 and 2025, respectively.

Furthermore, as stated in Note (6)(g), the other equity accounted investments of Excelsior Medical Co., Ltd. and its subsidiaries in its investee companies of \$4,319,876 thousand and \$4,153,341 thousand as of March 31, 2026 and 2025, respectively, and its share of comprehensive income of associates and joint ventures accounted for using equity method on these investee companies of gains \$102,944 thousand and gains \$93,968 thousand for the three months ended March 31, 2026 and 2025, respectively, were recognized solely on the financial statements prepared by these investee companies, but not reviewed by independent auditors.



Qualified Conclusion

Except for the adjustments, if any, as might have been determined to be necessary had the financial statements of certain consolidated subsidiaries and equity accounted investee companies described in the Basis for Qualified Conclusion paragraph above been reviewed by independent auditors, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Excelsior Medical Co., Ltd. and its subsidiaries as of March 31, 2026 and 2025, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2026 and 2025 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors’ review report are Kuo, Rou-Lan and Chen, Chun-Kuang.

KPMG

Taipei, Taiwan (Republic of China)

May 8, 2026

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors’ review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors’ review report and consolidated financial statements, the Chinese version shall prevail.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2026 AND 2025
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

ASSETS		March 31, 2026		December 31, 2025		March 31, 2025				LIABILITIES AND EQUITY		March 31, 2026		December 31, 2025		March 31, 2025	
		Amount	%	Amount	%	Amount	%					Amount	%	Amount	%	Amount	%
Current assets:										Current liabilities:							
1100	Cash and cash equivalents (Note (6)(a))	\$ 3,077,674	16	2,847,128	15	2,796,669	15	2100		Short-term borrowings (Note (6)(m))	\$ 386,784	2	1,343,221	7	518,257	2	
1110	Current financial assets at fair value through profit or loss (Note (6)(b))	28	-	-	-	-	-	2120		Current financial liabilities at fair value through profit or loss (Note (6)(b))	195	-	-	-	-	-	
1136	Current financial assets at amortized cost (Note (6)(d))	658,830	3	612,160	3	600,480	3	2130		Current contract liabilities	572,267	3	572,217	3	531,060	3	
1151	Notes receivable (Notes (6)(e), (7) and (8))	184,912	1	188,111	1	237,407	1	2150		Notes payable	4,336	-	6,367	-	1,256	-	
1152	Other notes receivable (Notes (6)(e), (7) and (8))	194,211	1	213,167	1	257,777	1	2170		Accounts payable (Note (7))	1,114,791	6	1,139,987	6	1,185,942	6	
1170	Accounts receivable (Notes (6)(e) and (7))	1,892,835	10	1,769,796	10	1,672,096	9	2200		Other payables (Notes (6)(n) and (7))	3,677,404	19	2,596,329	14	4,041,959	21	
1200	Other receivables (Notes (6)(e) and (7))	3,034,540	16	3,036,901	16	3,198,273	17	2230		Current tax liabilities	159,424	1	108,869	-	157,073	1	
130X	Inventories (Note (6)(f))	1,408,900	7	1,391,669	8	1,452,631	8	2280		Current lease liabilities (Notes (6)(p) and (7))	134,772	-	140,406	1	129,014	1	
1476	Other current financial assets (Note (8))	79,086	-	75,185	-	87,995	1	2399		Other current liabilities, others (Notes (6)(o) and (7))	292,924	1	284,607	1	302,208	2	
1479	Other current assets, others	282,259	2	232,175	1	231,686	1				6,342,897	32	6,192,003	32	6,866,769	36	
		10,813,275	56	10,366,292	55	10,535,014	56										
Non-current assets:										Non-Current liabilities:							
1517	Non-current financial assets at fair value through other comprehensive income (Note (6)(e))	841,435	4	881,474	5	627,432	3	2570		Long-term borrowings (Note (6)(m))	350,000	2	350,000	2	350,000	2	
1550	Investments accounted for using equity method (Note (6)(g))	4,319,876	22	4,216,105	22	4,156,677	22	2640		Deferred tax liabilities (Note (6)(s))	365,995	2	369,847	2	321,528	2	
1600	Property, plant and equipment (Notes (6)(i) and (8))	744,512	4	756,005	4	770,359	4	2650		Non-current lease liabilities (Notes (6)(p) and (7))	330,199	2	320,279	2	354,084	2	
1755	Right-of-use assets (Note (6)(j))	279,548	1	272,114	1	302,270	2			Net defined benefit liability (Note (6)(r))	5,635	-	5,020	-	4,023	-	
1760	Investment property, net (Notes (6)(k) and (8))	1,595,166	8	1,598,242	8	1,607,469	9	2670		Credit balance of investments accounted for using equity method (Note (6)(g))	-	-	-	-	3,336	-	
1780	Intangible assets (Note (6)(l))	45,321	-	46,757	-	47,312	-			Other non-current liabilities, others	13,913	-	15,441	-	19,486	-	
1840	Deferred tax assets (Note (6)(s))	108,296	1	115,355	1	114,718	1				1,065,742	6	1,060,587	6	1,052,457	6	
1930	Long-term notes and accounts receivable (Note (6)(e))	344,142	2	333,936	2	309,808	2			Total liabilities	7,408,639	38	7,252,590	38	7,919,226	42	
1975	Net defined benefit asset (Note (6)(r))	59,560	-	62,527	-	51,004	-			Equity attributable to owners of parent (Note (6)(t)):							
1980	Other non-current financial assets (Note (8))	301,496	2	316,480	2	205,809	1	3100		Share capital	1,883,674	10	1,715,674	9	1,633,975	9	
1990	Other non-current assets, others	11,276	-	11,910	-	30,514	-	3200		Capital surplus	4,248,985	22	3,390,833	18	3,382,788	18	
		8,650,628	44	8,610,905	45	8,223,372	44	3300		Retained earnings	3,152,654	16	3,740,835	20	3,195,076	17	
								3400		Other equity	347,983	2	344,945	2	356,121	2	
										Total equity attributable to owners of parent	9,633,296	50	9,192,287	49	8,567,960	46	
								36XX		Non-controlling interests (Notes (6)(h) and (t))	2,421,968	12	2,532,320	13	2,271,200	12	
										Total equity	12,055,264	62	11,724,607	62	10,839,160	58	
TOTAL ASSETS		\$ 19,463,903	100	18,977,197	100	18,758,386	100			TOTAL LIABILITIES AND EQUITY	\$ 19,463,903	100	18,977,197	100	18,758,386	100	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT EARNINGS PER SHARE)

		For the Three Months Ended March 31,			
		2026		2025	
		Amount	%	Amount	%
4000	Operating revenue (Notes (6)(w) and (7))	\$ 2,342,958	100	2,149,325	100
5000	Operating costs (Notes (6)(f) and (7))	1,843,672	79	1,693,552	79
	Gross profit from operations	499,286	21	455,773	21
5910	Less: Unrealized profit from sales	20,155	1	20,549	1
5920	Add: Realized profit from sales	17,396	1	22,363	1
		<u>496,527</u>	<u>21</u>	<u>457,587</u>	<u>21</u>
	Operating expenses:				
6100	Selling expenses (Note (7))	208,172	9	183,056	9
6200	Administrative expenses (Note (7))	104,433	4	96,839	4
6450	Expected credit loss (gain) (Note (6)(e))	3,520	-	(3,504)	-
		<u>316,125</u>	<u>13</u>	<u>276,391</u>	<u>13</u>
	Net operating income	<u>180,402</u>	<u>8</u>	<u>181,196</u>	<u>8</u>
	Non-operating income and expenses:				
7100	Interest income (Note (6)(y))	18,358	-	23,323	1
7010	Other income (Notes (6)(y) and (7))	1,687	-	617	-
7020	Other gains and losses (Notes (6)(y) and (7))	(1,402)	-	6,749	-
7050	Finance costs (Notes (6)(y) and (7))	(8,053)	-	(8,582)	-
7060	Share of profit of associates and joint ventures accounted for using equity method (Note (6)(g))	102,944	4	93,968	4
		<u>113,534</u>	<u>4</u>	<u>116,075</u>	<u>5</u>
7900	Profit before tax	293,936	12	297,271	13
7950	Less: Tax expense (Note (6)(s))	57,430	2	57,030	2
	Profit	<u>236,506</u>	<u>10</u>	<u>240,241</u>	<u>11</u>
	Other comprehensive income (loss):				
8310	Items that may not be reclassified subsequently to profit or loss:				
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	10,006	-	(28,520)	(1)
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss	(21,586)	(1)	11,152	-
8349	Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	3,847	-	(4,352)	-
	Total items that will not be reclassified subsequently to profit and loss	<u>(15,427)</u>	<u>(1)</u>	<u>(13,016)</u>	<u>(1)</u>
8360	Items that will be reclassified to profit or loss				
8361	Exchange differences on translation	59,159	3	46,330	2
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss	(11,223)	(1)	(18,966)	(1)
8399	Less: Income tax related to components of other comprehensive income that will be reclassified to profit or loss	167	-	(22)	-
	Total items that will be reclassified subsequently to profit and loss	<u>47,769</u>	<u>2</u>	<u>27,386</u>	<u>1</u>
	Other comprehensive income, net	<u>32,342</u>	<u>1</u>	<u>14,370</u>	<u>-</u>
8500	Total comprehensive income	<u>\$ 268,848</u>	<u>11</u>	<u>254,611</u>	<u>11</u>
	Profit attributable to:				
8610	Owners of parent	\$ 205,180	9	195,243	9
8620	Non-controlling interests	31,326	1	44,998	2
		<u>\$ 236,506</u>	<u>10</u>	<u>240,241</u>	<u>11</u>
	Comprehensive income attributable to:				
	Comprehensive income, attributable to former owner of business combination under common control	224,838	10	217,876	10
8720	Non-controlling interests	44,010	1	36,735	1
		<u>\$ 268,848</u>	<u>11</u>	<u>254,611</u>	<u>11</u>
	Earnings per share (Note (6)(v))				
9750	Basic earnings per share (NT dollars)	<u>\$ 1.12</u>		<u>1.19</u>	
9850	Diluted earnings per share (NT dollars)	<u>\$ 1.12</u>		<u>1.19</u>	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Equity attributable to owners of parent					Total other equity interest				Total equity
	Share capital		Retained earnings			Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Equity attributable to owners of parent	Non-controlling interests	
	Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings					
Balance as of January 1, 2025	\$ 1,633,975	3,382,788	1,052,282	-	2,567,708	(10,729)	344,217	8,970,241	2,387,112	11,357,353
Profit for the year	-	-	-	-	195,243	-	-	195,243	44,998	240,241
Other comprehensive income (loss) for the year	-	-	-	-	-	25,623	(2,990)	22,633	(8,263)	14,370
Total comprehensive income (loss) for the year	-	-	-	-	195,243	25,623	(2,990)	217,876	36,735	254,611
Appropriation and distribution of retained earnings:										
Cash dividends of ordinary share	-	-	-	-	(620,910)	-	-	(620,910)	-	(620,910)
Changes in ownership interests in subsidiaries	-	-	-	-	753	-	-	753	-	753
Changes in non-controlling interests	-	-	-	-	-	-	-	-	(152,647)	(152,647)
Balance at March 31, 2025	\$ 1,633,975	3,382,788	1,052,282	-	2,142,794	14,894	341,227	8,567,960	2,271,200	10,839,160
Balance at January 1, 2026	\$ 1,715,674	3,390,833	1,130,936	-	2,609,899	(43,667)	388,612	9,192,287	2,532,320	11,724,607
Profit for the year	-	-	-	-	205,180	-	-	205,180	31,326	236,506
Other comprehensive income (loss) for the year	-	-	-	-	-	45,035	(25,377)	19,658	12,684	32,342
Total comprehensive income (loss) for the year	-	-	-	-	205,180	45,035	(25,377)	224,838	44,010	268,848
Appropriation and distribution of retained earnings:										
Cash dividends of ordinary share	-	-	-	-	(809,980)	-	-	(809,980)	-	(809,980)
Changes in equity of associates and joint ventures accounted for using equity method	-	-	-	-	(1)	-	-	(1)	-	(1)
Capital increased by cash	168,000	840,000	-	-	-	-	-	1,008,000	-	1,008,000
Changes in ownership interests in subsidiaries	-	-	-	-	16,620	-	(16,620)	-	-	-
Share-based payments	-	18,152	-	-	-	-	-	18,152	2,912	21,064
Changes in non-controlling interests	-	-	-	-	-	-	-	-	(157,274)	(157,274)
Balance at March 31, 2026	\$ 1,883,674	4,248,985	1,130,936	-	2,021,718	1,368	346,615	9,633,296	2,421,968	12,055,264

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	For the Three Months Ended March 31,	
	2026	2025
Cash flows from operating activities:		
Profit before tax	\$ 293,936	297,271
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expense	72,315	75,493
Amortization expense	2,086	1,786
Expected credit (gain) loss	3,520	(3,504)
Net gain on financial assets or liabilities at fair value through profit or loss	(454)	(1,261)
Interest expense	8,053	8,582
Interest income	(18,358)	(23,323)
Dividend income	(612)	-
Compensation cost from share-based payments	21,064	-
Share of profit of associates and joint ventures accounted for using equity method	(102,944)	(93,968)
Gain on disposal of property, plan and equipment	(54)	(413)
Unrealized profit from sales	20,155	20,549
Realized profit from sales	(17,396)	(22,363)
Profit from lease modification	(261)	(34)
Total adjustments to reconcile profit	<u>(12,886)</u>	<u>(38,456)</u>
Changes in operating assets and liabilities:		
Changes in operating assets:		
Notes receivable	5,275	(17,439)
Accounts receivable	(113,758)	82,734
Other receivables and notes	22,807	204,406
Inventories	(27,979)	(65,664)
Net defined benefit asset	2,967	2,947
Other current assets	(49,402)	(58,133)
Other operating assets	-	(26,474)
Total changes in operating assets	<u>(160,090)</u>	<u>122,377</u>
Changes in operating liabilities:		
Contract liabilities	50	(12,535)
Notes payable	(2,031)	(675)
Accounts payable	(25,196)	208,903
Other payables	114,031	(2,039,141)
Other current liabilities	8,317	(9,525)
Net defined benefit liability	615	(345)
Other operating liabilities	(1,595)	292
Total changes in operating liabilities	<u>94,191</u>	<u>(1,853,026)</u>
Total changes in operating assets and liabilities	<u>(65,899)</u>	<u>(1,730,649)</u>
Total adjustments	<u>(78,785)</u>	<u>(1,769,105)</u>
Cash inflow (outflow) generated from operations	215,151	(1,471,834)
Interest received	16,614	25,330
Income taxes paid	(7,767)	(3,913)
Net cash flows from (used in) operating activities	<u>223,998</u>	<u>(1,450,417)</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Cash flows (used in) from investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	(22,230)	-
Proceeds from disposal of financial assets at fair value through other comprehensive income	72,251	-
Acquisition of financial assets at amortized cost	(146,000)	(101,500)
Proceeds from disposal of financial assets at amortized cost	100,000	262,281
Proceeds from disposal of financial assets at fair value through profit or loss	621	1,378
Acquisition of property, plant and equipment	(33,578)	(29,953)
Proceeds from disposal of property, plant and equipment	54	413
Decrease in refundable deposits	14,775	1,902
Acquisition of intangible assets	(22)	(1,366)
Other financial assets	(3,692)	13,241
Other non-current assets	177	(16,020)
Dividends received	612	-
Net cash flows (used in) from investing activities	<u>(17,032)</u>	<u>130,376</u>
Cash flows from (used in) financing activities:		
Decrease in short-term borrowings	(956,437)	(399,274)
Proceeds from long-term borrowings	-	350,000
Increase in guarantee deposits received	67	4,563
Payment of lease liabilities	(36,498)	(33,467)
Capital increased by cash	1,008,000	-
Interest paid	(8,896)	(7,402)
Net cash flows from (used in) financing activities	<u>6,236</u>	<u>(85,580)</u>
Effect of exchange rate changes on cash and cash equivalents	17,344	13,086
Net increase (decrease) in cash and cash equivalents	230,546	(1,392,535)
Cash and cash equivalents at beginning of period	<u>2,847,128</u>	<u>4,189,204</u>
Cash and cash equivalents at end of period	<u>\$ 3,077,674</u>	<u>2,796,669</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(1) Company History

Excelsior Medical Co., Ltd. (the Company) was incorporated on March 15, 1988 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235, Taiwan, R.O.C.. The Company and its subsidiaries (the Group) engaged primarily in the sale of medical supplies and equipment, medicines and home medical devices.

The Company's shares were traded on the Taipei Exchange (formerly the GreTai Securities Market) from June 8, 2001 to December 31, 2007 and have been traded on the Taiwan Stock Exchange since December 31, 2007.

(2) Financial Statements Authorization Date and Authorization Process

The consolidated financial statements were authorized for issuance by the Board of Directors on May 8, 2026.

(3) New Standards, Amendments and Interpretations Adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2026:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

- (b) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

<u>Standards or Interpretations</u>	<u>Content of amendment</u>	<u>Effective date per IASB</u>
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none">• A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities.• Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.• Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.	<p>January 1, 2027</p> <p>note: On September 25, 2025, the FSC issued a press release announcing that Taiwan will adopt IFRS 18 beginning in 2028. Entities that need to adopt the new standard earlier may do with the endorsement of the FSC.</p>

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(4) Summary of material accounting policies

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS Accounting Standards endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2025. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2025.

(b) Basis of consolidation

1. List of subsidiaries in the consolidated financial statements :

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding			Note
			March 31, 2026	December 31, 2025	March 31, 2025	
The Company	Dynamic Medical Technologies Inc. (“Dynamic”)	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	33.97 %	33.97 %	33.96 %	Note 1 ~ 2
”	Excelsior Healthcare Co., Limited (Excelsior Healthcare)	Investment business	100.00 %	100.00 %	100.00 %	
”	Arich Enterprise Co., Ltd. (Arich)	Sale of medicines, and logistics service	40.00 %	40.00 %	40.00 %	Note 1
”	Excelsior Asset Management Co., Ltd. (“Excelsior Asset”)	Sales of medical equipment, precision instrument and real estate	100.00 %	100.00 %	100.00 %	
The Company and Excelsior Healthcare	Excelsior Medical (HK) Co., Limited (“Hong Kong Excelsior”)	Investment business	100.00 %	100.00 %	100.00 %	
Dynamic	Dynamic Medical Technologies (Hong Kong) Ltd. (“Hong Kong Dynamic”)	Sale of cosmetic health care products	100.00 %	100.00 %	100.00 %	
”	CYJ International Taiwan Inc. (CYJ Taiwan)	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	55.41 %	55.41 %	55.41 %	
The Company and Dynamic	Excelsior Beauty Co., Ltd. (“Excelsior Beauty”)	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	94.91 %	94.91 %	94.91 %	
Hong Kong Dynamic	Guangzhou Dynamic Inc. (“Guangzhou Dynamic”)	Sale and maintenance of medical equipment	100.00 %	100.00 %	100.00 %	Note 3
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd. (Arich Best Chain)	Logistics business	100.00 %	100.00 %	100.00 %	”
Excelsior Healthcare	EG Healthcare, Inc.	Sale and lease of medical equipment, and medical management consultancy service	99.99 %	99.99 %	99.99 %	”
”	Excelsior Investment (Malaysia) Co., Ltd	Investment business	100.00 %	100.00 %	100.00 %	”

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding			Note
			March 31, 2026	December 31, 2025	March 31, 2025	
Hong Kong Excelsior	SinoExcelsior Investment Inc. ("SinoExcelsior Investment")	Sale of medical equipment, and medical management consultancy service	100.00 %	100.00 %	100.00 %	Note 3
Excelsior Investment (Malaysia) Co., Ltd.	Renal Laboratories Sdn. Bhd.	Manufacture of medical equipment	81.90 %	81.90 %	81.90 %	"
"	Medi-Chem Systems Sdn. Bhd.	Sale of medical equipment	70.00 %	70.00 %	70.00 %	"
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Lease business	100.00 %	100.00 %	100.00 %	"

Note 1: Although the Company holds less than 50% of the shares of Dynamic and Arich, these companies' other equity shares are highly separated. Therefore, the Company still maintains control over Dynamic and Arich, and these companies are included in the consolidated financial statements.

Note 2: The Company bought the fractional shares of Dynamic in September 2025 acquiring 0.004%, of Dynamic's shares, while still maintaining control over Dynamic.

Note 3: Non-significant subsidiaries, which were not reviewed by independent auditors.

2.Subsidiaries excluded from the consolidated financial statements: None.

(c) Classification of Current and Non-Current Assets and Liabilities

The Group classifies the asset as current under one of the following criteria, and all other assets are classified as non-current.

- 1.It is expected to be realized, or intended to be sold or consumed, in the normal operating cycle;
- 2.It is held primarily for the purpose of trading;
- 3.It is expected to be realized within twelve months after the reporting period; or
- 4.The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies the liability as current under one of the following criteria, and all other liabilities are classified as non-current.

- 1.It is expected to be settled in the normal operating cycle;
- 2.It is held primarily for the purpose of trading;
- 3.It is due to be settled within twelve months after the reporting period; or
- 4.The Group does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(d) Income Taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are measured by multiplying together pre-tax income for the interim reporting period and the managements best estimate period annual tax rate.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(e) Employee Benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events.

(f) Share-based Payment

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes.

Grant date of a share-based payment award is the date which the board of directors and the employees have made an agreement on the price and number of the new award.

(5) Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty

The preparation of the consolidated financial statements in conformity with the Regulations and IFRS Accounting Standards (in accordance with IAS 34 “Interim Financial Reporting” and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2025. For related information, please refer to note (5) of the consolidated financial statements for the year ended December 31, 2025.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(6) Explanation of Significant Accounts

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the interim consolidated financial statements for the current period and the 2025 consolidated financial statements. Please refer to Note (6) to the 2025 annual consolidated financial statements.

(a) Cash and cash equivalents

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Cash on hand, demand deposits and checking accounts	\$ 1,872,819	2,180,593	2,106,728
Time deposits	<u>1,204,855</u>	<u>666,535</u>	<u>689,941</u>
Cash and cash equivalents in consolidated statement of cash flows	<u>\$ 3,077,674</u>	<u>2,847,128</u>	<u>2,796,669</u>

The Group interest risk and sensibility analysis of the financial assets and liabilities was disclosed in Note (6)(y).

(b) Financial assets or financial liabilities at fair value through profit or loss

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Mandatorily measured at fair value through profit or loss:			
Forward foreign exchange contracts	\$ <u>28</u>	<u>-</u>	<u>-</u>
Held-for-trading financial liabilities			
Forward foreign exchange contracts	\$ <u>195</u>	<u>-</u>	<u>-</u>

The Group holds derivative financial instruments to hedge certain foreign exchange and interest rate risk exposures arising from its operating, financing and investing activities. The following derivative instruments, without the application of hedge accounting, were classified as mandatorily measured at fair value through profit or loss and held-for-trading financial liabilities:

Forward foreign exchange contracts:

	<u>March 31, 2026</u>		
	<u>Amount (in thousands)</u>	<u>Currency</u>	<u>Maturity period</u>
Forward foreign exchange contracts purchased	JPY 93,094	JPY to TWD	2026.05
Forward foreign exchange contracts purchased	JPY 55,183	JPY to TWD	2026.04
Forward foreign exchange contracts purchased	JPY 56,910	JPY to TWD	2026.04

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Financial assets at fair value through other comprehensive income

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Equity investments at fair value through other comprehensive income			
Domestic listed shares	\$ 24,643	2,659	2,537
Foreign listed shares	230,809	248,855	106,064
Domestic unlisted shares	123,329	132,312	144,260
Foreign unlisted shares	<u>462,654</u>	<u>497,648</u>	<u>374,571</u>
Total	<u>\$ 841,435</u>	<u>881,474</u>	<u>627,432</u>

1. Equity investments at fair value through other comprehensive income

The Group designated the investments shown above as equity securities at fair value through other comprehensive income because these equity securities represent those investments that the Group intends to hold for long term for strategic purposes.

The Group has sold its common stocks designated at fair value through other comprehensive income because of operation strategies for the three months ended March 31, 2026. The shares sold had a fair value of \$72,251 thousand. The Group realized a gain of \$48,930 thousand, which was included in other comprehensive income (equity attributable to owners of parent), and thereafter, was transferred to retained earnings from other equity.

There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments for the three months ended March 31, 2025.

2. For credit risk and market risk, please refer to Note (6)(z).

3. As of March 31, 2026, December 31, 2025 and March 31, 2025, the aforesaid financial assets were not pledged as collateral.

(d) Financial assets measured at amortized cost

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Time deposits with original maturity of more than 3 months	<u>\$ 658,830</u>	<u>612,160</u>	<u>600,480</u>

The Group has assessed that these financial assets are held to maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments have been classified as financial assets measured at amortized cost.

The market interest rates of the time deposits with original maturity of more than 3 months were 1.100%~1.70%, 1.100%~1.70% and 1.255%~4.15% as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(e) Notes receivable, accounts receivable, lease payment receivable and other receivables

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Notes receivable	\$ 185,601	191,341	239,049
Other notes receivable	194,211	213,167	257,777
Accounts receivable	1,837,027	1,715,019	1,671,594
Receivable installments	528	809	4,644
Receivable installments - OCI	3,224	3,286	-
Lease payment receivable	457,985	440,703	367,661
Other receivables	3,036,853	3,039,008	3,200,829
Less: Loss allowance	(59,154)	(55,766)	(60,979)
Allowance for sales returns	(5,488)	(5,543)	(5,061)
Unrealized interests income	(147)	(113)	(153)
	<u>\$ 5,650,640</u>	<u>5,541,911</u>	<u>5,675,361</u>

The Group has assessed a portion of its trade receivables that was held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; therefore, such trade receivables were measured at fair value through other comprehensive income.

Arich Enterprise Co., Ltd. (“Arich”) engages in medical logistics services, providing inventory management services, logistics services, customer service and domestic transportation planning services. Arich recognizes the medical logistics service revenue at a percentage of the net profit on its sale of medicines. The inventories for medical logistics services do not belong to Arich. The receivables from customers and the payables to medical companies are classified as other notes receivable, other trade receivables, other notes payable, and other trade payables.

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information, including macroeconomic and relevant industry information. The loss allowance provision were determined as follows:

	<u>March 31, 2026</u>		
	<u>Gross carrying</u> <u>amount</u>	<u>Weighted-</u> <u>average loss</u> <u>rate</u>	<u>Loss allowance</u> <u>provision</u>
Current	\$ 5,550,158	0.35%	(19,309)
1 to 90 days past due	129,103	8.54%	(11,027)
91 to 180 days past due	7,035	28.59%	(2,011)
181 to 365 days past due	2,539	20.20%	(513)
More than 365 days past due	26,447	99.42%	(26,294)
	<u>\$ 5,715,282</u>		<u>(59,154)</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	December 31, 2025		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 5,506,809	0.35%	(19,130)
1 to 90 days past due	64,103	13.35%	(8,557)
91 to 180 days past due	4,730	28.33%	(1,340)
181 to 365 days past due	1,639	49.05%	(804)
More than 365 days past due	<u>25,939</u>	99.98%	<u>(25,935)</u>
	<u>\$ 5,603,220</u>		<u>(55,766)</u>
	March 31, 2025		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 5,613,829	0.28%	(15,483)
1 to 90 days past due	81,131	6.79%	(5,507)
91 to 180 days past due	7,347	25.64%	(1,884)
181 to 365 days past due	2,187	58.89%	(1,288)
More than 365 days past due	<u>36,907</u>	99.76%	<u>(36,817)</u>
	<u>\$ 5,741,401</u>		<u>(60,979)</u>

The Group's lease payment receivables were as follows:

	Gross investment in the lease	Unearned finance income	Present value of minimum lease payments receivable
March 31, 2026			
Less than one year	\$ 138,443	(23,124)	115,319
Between one and five years	<u>388,353</u>	<u>(45,687)</u>	<u>342,666</u>
	<u>\$ 526,796</u>	<u>(68,811)</u>	<u>457,985</u>
December 31, 2025			
Less than one year	\$ 124,683	(16,500)	108,183
Between one and five years	<u>373,754</u>	<u>(41,234)</u>	<u>332,520</u>
	<u>\$ 498,437</u>	<u>(57,734)</u>	<u>440,703</u>
March 31, 2025			
Less than one year	\$ 64,763	(4,411)	60,352
Between one and five years	<u>359,306</u>	<u>(51,997)</u>	<u>307,309</u>
	<u>\$ 424,069</u>	<u>(56,408)</u>	<u>367,661</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group entered into finance lease arrangements for certain vehicles and equipment. All leases were denominated in New Taiwan dollars. The term of finance leases entered into was 1 to 5 years.

The lease payment receivables as of March 31, 2026, December 31, 2025 and March 31, 2025 were neither past due nor impaired.

The movement in the allowance for notes and trade receivable was as follows:

	For the Three Months Ended March 31,	
	2026	2025
Balance as of January 1	\$ 55,766	64,032
Impairment losses recognized (reversed)	3,520	(3,504)
Effect of movements in exchange rate	(132)	451
Balance as of March 31	<u>\$ 59,154</u>	<u>60,979</u>

As of March 31, 2026, December 31, 2025 and March 31, 2025, the receivables from installment sales were \$3,752 thousand, \$4,095 thousand and \$4,644 thousand, respectively, and the related unrealized interest income were \$147 thousand, \$113 thousand and \$153 thousand, respectively.

(f) Inventories

	March 31,	December 31,	March 31,
	2026	2025	2025
Merchandise	\$ 1,339,610	1,359,048	1,394,444
Inventory in-transit	69,290	32,621	58,187
Total	<u>\$ 1,408,900</u>	<u>1,391,669</u>	<u>1,452,631</u>

The details of cost of goods sold were as follows :

	For the Three Months Ended March 31,	
	2026	2025
Cost of goods sold	\$ 1,626,771	1,483,172
(Reversal) losses on inventory valuation and obsolescence	(4,989)	2,075
Service Cost	78,433	68,737
Repair and maintenance costs	34,047	35,038
Others operating costs	109,410	104,530
Total	<u>\$ 1,843,672</u>	<u>1,693,552</u>

The factor leading to the net realizable value of inventories lower than the cost no longer exists, resulting in the net realizable value and the recognition of a gain on inventory recoveries for the three months ended March 31, 2026.

Inventory valuation and obsolescence due to write-down of inventory to net realizable value or slow-moving inventory were recognized as cost of operations for the three months ended March 31, 2025.

As of March 31, 2026, December 31, 2025 and March 31, 2025, none of the combined company's inventories had been provided with pledge guarantees.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(g) Investments accounted for using equity method

A summary of the Group's financial information for investments accounted for using the equity method at the reporting date is as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Associates	<u>\$ 4,319,876</u>	<u>4,216,105</u>	<u>4,153,341</u>

1. Associates

Associates which are material to the Group consisted of the followings:

Name of Associates	Nature of Relationship with the Group	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights		
			March 31, 2026	December 31, 2025	March 31, 2025
Asia Best Healthcare	Healthcare management services	Cayman Islands	48.47 %	48.47 %	48.47 %
Asia Best Life Care Co., Ltd.	Long-term care and rehabilitation services, leasing business, sale of medical consumables and information services	Taiwan	49.02 %	49.02 %	49.38 %

1) Asia Best Healthcare:

	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	\$ 1,157,592	1,026,727	971,282
Non-current assets	1,870,495	1,830,642	2,388,387
Current liabilities	(258,009)	(136,780)	(256,890)
Non-Current liabilities	<u>(1,438,914)</u>	<u>(1,417,287)</u>	<u>(1,821,107)</u>
Net assets	<u>\$ 1,331,164</u>	<u>1,303,302</u>	<u>1,281,672</u>
Net assets attributable to the Group	<u>\$ 632,438</u>	<u>618,784</u>	<u>608,755</u>
		For the Three Months Ended March 31,	
		2026	2025
Operating revenue		<u>\$ 41,989</u>	<u>34,113</u>
Profit		\$ 12,338	28,654
Other comprehensive income (loss)		<u>(8,612)</u>	<u>(18,416)</u>
Total comprehensive income		<u>\$ 3,726</u>	<u>10,238</u>
Comprehensive income attributable to the Group		<u>\$ 1,806</u>	<u>4,963</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Asia Best Life Care Co., Ltd.:

	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	\$ 814,045	780,931	667,564
Non-current assets	1,638,772	1,650,824	1,737,008
Current liabilities	(115,364)	(117,647)	(133,935)
Non-Current liabilities	(302,918)	(317,861)	(359,452)
Net assets	<u>\$ 2,034,535</u>	<u>1,996,247</u>	<u>1,911,185</u>
Net assets attributable to the Group	<u>\$ 1,054,192</u>	<u>1,035,423</u>	<u>958,815</u>
		For the Three Months Ended March 31,	
		2026	2025
Operating revenue		<u>\$ 61,801</u>	<u>94,963</u>
Profit		\$ 38,287	34,775
Other comprehensive income		-	-
Total comprehensive income		<u>\$ 38,287</u>	<u>34,775</u>
Comprehensive income attributable to the Group		<u>\$ 18,768</u>	<u>17,171</u>

The Group's financial information for investments accounted for using equity method that are individually insignificant was as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Carrying amount of individually insignificant associates' equity	<u>\$ 2,633,246</u>	<u>2,561,898</u>	<u>2,544,113</u>
		For the Three Months Ended March 31,	
		2026	2025
Attributable to the Group			
Profit		\$ 78,194	62,907
Other comprehensive income		(27,987)	1,111
Total comprehensive income		<u>\$ 50,207</u>	<u>64,018</u>

None of the Group's investments using the equity method is provided as a pledge.

2.The unreviewed financial statements of investments accounted for using equity method

Investments were accounted for by using the equity method, and the share of profit or loss and other comprehensive income of those investments were calculated based on the financial statements that have not been reviewed.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

Subsidiaries	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights		
		March 31, 2026	December 31, 2025	March 31, 2025
Dynamic	Taiwan	66.03 %	66.03 %	66.04 %
Arich	Taiwan	60.00 %	60.00 %	60.00 %

The summarized financial information below represents amounts before intragroup eliminations were as follows:

1. Collective financial information of Dynamic and its subsidiaries:

	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	\$ 1,944,014	1,878,616	1,909,710
Non-current assets	1,206,998	1,248,031	1,053,783
Current liabilities	(989,142)	(869,772)	(959,567)
Non-Current liabilities	(357,373)	(364,589)	(358,306)
Net assets	<u>\$ 1,804,497</u>	<u>1,892,286</u>	<u>1,645,620</u>
Non-controlling interests	<u>\$ 1,111,090</u>	<u>1,239,231</u>	<u>877,081</u>

	For the Three Months Ended March 31,	
	2026	2025
Operating revenue	<u>\$ 342,776</u>	<u>351,235</u>
Net income	\$ 35,219	46,898
Other comprehensive income (loss)	40,973	(10,162)
Total comprehensive income	<u>\$ 76,192</u>	<u>36,736</u>
Profit, attributable to non-controlling interests	<u>\$ 19,644</u>	<u>28,392</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 24,752</u>	<u>35,248</u>

	For the Three Months Ended March 31,	
	2026	2025
Net cash flows from operating activities	\$ (29,718)	(47,574)
Net cash flows from investing activities	18,988	136,001
Net cash flows from financing activities	(23,586)	(21,987)
Effect of exchange rate changes on cash and cash equivalents	968	(890)
Net (decrease) increase in cash and cash equivalents	<u>\$ (33,348)</u>	<u>65,550</u>
Dividends paid to non-controlling interests	<u>\$ -</u>	<u>-</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2. Collective financial information of Arich and its subsidiaries:

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Current assets	\$ 4,166,607	4,518,404	4,750,866
Non-current assets	683,365	741,319	621,822
Current liabilities	(2,816,165)	(3,132,231)	(3,388,256)
Non-Current liabilities	<u>(107,673)</u>	<u>(116,095)</u>	<u>(128,940)</u>
Net assets	<u>\$ 1,926,134</u>	<u>2,011,397</u>	<u>1,855,492</u>
Non-controlling interests	<u>\$ 1,155,658</u>	<u>1,206,816</u>	<u>1,113,273</u>
		For the Three Months Ended March 31,	
		<u>2026</u>	<u>2025</u>
Operating revenue		<u>\$ 411,381</u>	<u>393,801</u>
Net income		\$ 19,175	28,668
Other comprehensive loss		<u>(27,976)</u>	<u>(5,419)</u>
Total comprehensive (loss) income		<u>\$ (8,801)</u>	<u>23,249</u>
Profit, attributable to non-controlling interests		<u>\$ 11,505</u>	<u>17,201</u>
Comprehensive income, attributable to non-controlling interests		<u>\$ 6,224</u>	<u>13,949</u>
		For the Three Months Ended March 31,	
		<u>2026</u>	<u>2025</u>
Net cash flows from operating activities		\$ 255,745	(1,499,171)
Net cash flows from investing activities		3,183	14,060
Net cash flows from financing activities		<u>(566,532)</u>	<u>(14,548)</u>
Net decrease in cash and cash equivalents		<u>\$ (307,604)</u>	<u>(1,499,659)</u>
Dividends paid to non-controlling interests		<u>\$ -</u>	<u>-</u>

(i) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Group for the nine months ended March 31, 2026 and 2025 were as follows:

	<u>Land</u>	<u>Buildings</u>	<u>Medical equipment</u>	<u>Miscellaneous equipment</u>	<u>Leased Improvement</u>	<u>Equipment to be inspected and construction in progress</u>	<u>Total</u>
Carrying amount:							
Balance as of January 1, 2026	\$ <u>144,747</u>	<u>165,608</u>	<u>230,997</u>	<u>159,264</u>	<u>9,776</u>	<u>45,613</u>	<u>756,005</u>
Balance as of March 31, 2026	\$ <u>146,503</u>	<u>166,816</u>	<u>231,312</u>	<u>160,857</u>	<u>9,776</u>	<u>29,248</u>	<u>744,512</u>
Balance as of January 1, 2025	\$ <u>140,507</u>	<u>162,669</u>	<u>255,090</u>	<u>186,118</u>	<u>12,195</u>	<u>39,018</u>	<u>795,597</u>
Balance as of March 31, 2025	\$ <u>142,081</u>	<u>164,459</u>	<u>224,283</u>	<u>168,057</u>	<u>11,590</u>	<u>59,889</u>	<u>770,359</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

There were no significant additions, disposal, or recognition and reversal of impairment losses of investment property for the three months ended March 31, 2026 and 2025. Information on depreciation for the period is discussed in note (12). Please refer to note (6)(j) to the 2025 annual consolidated financial statements for other related information.

(j) Right-of-use assets

The Group leases many assets including buildings, machinery and other equipment. Information about leases for which the Group as a lessee was presented below:

	<u>Buildings</u>	<u>Machinery and equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost:				
Balance as of January 1, 2026	\$ 592,254	10,027	404	602,685
Additions	45,547	-	-	45,547
Write-off	(19,153)	-	-	(19,153)
Effect of movements in exchange rates	(628)	-	(5)	(633)
Balance as of March 31, 2026	<u>\$ 618,020</u>	<u>10,027</u>	<u>399</u>	<u>628,446</u>
Balance as of January 1, 2025	\$ 551,249	7,737	-	558,986
Additions	5,317	4,539	-	9,856
Write-off	(14,653)	-	-	(14,653)
Effect of movements in exchange rates	612	-	-	612
Balance as of March 31, 2025	<u>\$ 542,525</u>	<u>12,276</u>	<u>-</u>	<u>554,801</u>
Accumulated depreciation and impairment losses:				
Balance as of January 1, 2026	\$ 325,789	4,587	195	330,571
Depreciation for the year	28,457	781	75	29,313
Write-off	(10,854)	-	-	(10,854)
Effect of movements in exchange rates	(129)	-	(3)	(132)
Balance as of March 31, 2026	<u>\$ 343,263</u>	<u>5,368</u>	<u>267</u>	<u>348,898</u>
Balance as of January 1, 2025	\$ 229,593	3,774	-	233,367
Depreciation for the year	27,854	718	-	28,572
Write-off	(9,500)	-	-	(9,500)
Effect of movements in exchange rates	92	-	-	92
Balance as of March 31, 2025	<u>\$ 248,039</u>	<u>4,492</u>	<u>-</u>	<u>252,531</u>
Carrying amount:				
Balance as of January 1, 2026	<u>\$ 266,465</u>	<u>5,440</u>	<u>209</u>	<u>272,114</u>
Balance as of March 31, 2026	<u>\$ 274,757</u>	<u>4,659</u>	<u>132</u>	<u>279,548</u>
Balance as of January 1, 2025	<u>\$ 321,656</u>	<u>3,963</u>	<u>-</u>	<u>325,619</u>
Balance as of March 31, 2025	<u>\$ 294,486</u>	<u>7,784</u>	<u>-</u>	<u>302,270</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

For the three months ended March 31, 2026 and 2025, the Group leases storage room, machinery and parking space under operating lease, please refer to Note (6)(q).

(k) Investment property

Investment properties are the assets hold by the Group. The period of rental investment properties that cannot be terminated originally is 15 years.

	Owned property		Total
	Land	Buildings	
Book value:			
Balance at January 1, 2026	\$ <u>1,266,920</u>	<u>331,322</u>	<u>1,598,242</u>
Balance as of March 31, 2026	\$ <u>1,266,920</u>	<u>328,246</u>	<u>1,595,166</u>
Balance as of January 1, 2025	\$ <u>1,266,920</u>	<u>343,625</u>	<u>1,610,545</u>
Balance as of March 31, 2025	\$ <u>1,266,920</u>	<u>340,549</u>	<u>1,607,469</u>

As of March 31, 2026, December 31, 2025 and March 31, 2025, the investment property of the Group had been pledged as collateral , please refer to Note (8).

(l) Intangible assets

	Goodwill	Software	Other	Total
			intangible	
			assets	
Book value:				
Balance as of January 1, 2026	\$ <u>29,389</u>	<u>9,575</u>	<u>7,793</u>	<u>46,757</u>
Balance as of March 31, 2026	\$ <u>29,573</u>	<u>8,361</u>	<u>7,387</u>	<u>45,321</u>
Balance as of January 1, 2025	\$ <u>28,945</u>	<u>8,762</u>	<u>9,417</u>	<u>47,124</u>
Balance as of March 31, 2025	\$ <u>29,110</u>	<u>9,191</u>	<u>9,011</u>	<u>47,312</u>

There were no significant additions, disposal, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2026 and 2025. Information on amortization for the period is discussed in Note (12). Please refer to Note (6)(m) to the 2025 annual consolidated financial statements for other related information.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(m) Long and short-term borrowings

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Secured bank loans	\$ 710,000	732,000	777,000
Unsecured bank loans	26,784	961,221	91,257
Total	<u>\$ 736,784</u>	<u>1,693,221</u>	<u>868,257</u>
Unused credit lines	<u>\$ 4,652,067</u>	<u>3,446,199</u>	<u>4,936,900</u>
Range of interest rates	<u>1.85%~4.26%</u>	<u>1.73%~6.45%</u>	<u>1.78%~6.90%</u>

Please refer to Note (8) for details of the Group's assets pledged as collateral for bank borrowings.

The Group's interest risk and sensitivity analysis of financial assets and liabilities were disclosed in Note (6)(y).

(n) Other payables

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Logistics services payable	\$ 2,292,312	2,110,545	2,834,540
Dividend payable	967,254	-	773,557
Others	417,838	485,784	433,862
	<u>\$ 3,677,404</u>	<u>2,596,329</u>	<u>4,041,959</u>

(o) Provisions

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Warranties	<u>\$ 14,864</u>	<u>16,628</u>	<u>16,760</u>
			Warranties
Balance as of January 1, 2026			\$ 16,628
Additions			2,155
Provisions reversed or used			(3,919)
Balance as of March 31, 2026			<u>\$ 14,864</u>
Balance as of January 1, 2025			\$ 18,241
Additions			2,846
Provisions reversed or used			(4,327)
Balance as of March 31, 2025			<u>\$ 16,760</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Warranties

The provision for warranty claims represents the present value of management's best estimate of the future outflow of economic benefits that will be required under the Group's obligations for warranties under local sale of goods legislation. The estimate had been made on the basis of historical warranty trends and may vary as a result of other events affecting product quality.

(p) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Current	\$ <u>134,772</u>	<u>140,406</u>	<u>129,014</u>
Non-current	\$ <u>330,199</u>	<u>320,279</u>	<u>354,084</u>

For the maturities analysis, please refer to Note (6)(z).

The amounts recognized in profit or loss were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Interest on lease liabilities	\$ <u>2,150</u>	<u>2,022</u>
Income from sub-leasing right-of-use assets	\$ <u>8,383</u>	<u>3,842</u>
Expenses relating to short-term leases	\$ <u>2,014</u>	<u>3,214</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Total cash outflow for leases	\$ <u>40,662</u>	<u>38,703</u>

1. Buildings leases

The Group leases buildings for its office space. The leases of office space typically run for a period of 2 to 10 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The Group sub-leases some of its right-of-use assets under operating leases; please refer to Note (6)(q).

2. Other leases

The Group leases machinery and other equipment, with lease terms of 1 to 5 years. In some cases, the Group has options to purchase the assets at the end of the contract term.

The Group also leases storage room, machinery and parking space with contract terms of 1 year to 3 years. These leases are short-term or leases of low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(q) Operating leases

Operating leases relate to leases and subleases of housing and leases of equipments with lease terms between 1 to 10 years. The leasees does not have bargain purchase options to acquire the leased housing and equipments at the expiration of the lease periods.

A maturity analysis of lease payments, showing the undiscounted lease payments to be received after the reporting date are as follows:

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Within 1 year	\$ 9,107	11,541	7,707
1 to 5 years	1,163	1,403	514
More than 5 years	-	-	-
	<u>\$ 10,270</u>	<u>12,944</u>	<u>8,221</u>

(r) Employee benefits

1. Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2025 and 2024.

The expenses recognized in profit or loss for the Group were as follows:

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Operating costs and expenses	<u>\$ 231</u>	<u>150</u>

2. Defined contribution plans

The Group's expenses for the pension plan contributions to the Bureau of Labor Insurance for the three months ended March 31, 2026 and 2025 were as follows:

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Operating costs and expenses	<u>\$ 8,972</u>	<u>8,322</u>

3. The foreign Company's pension costs under the local laws were \$1,007 thousand and \$911 thousand for the three months ended March 31, 2026 and 2025, respectively.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(s) Income taxes

The components of income tax were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Current tax expense		
Current period	\$ 58,801	59,771
Adjustment for prior periods	(564)	-
	<u>58,237</u>	<u>59,771</u>
Deferred tax expense		
Current period	(807)	(2,741)
Income tax expense from continuing operations	<u>\$ 57,430</u>	<u>57,030</u>

The amount of income tax recognized directly in equity for 2025 was as follows; no income tax was recognized directly in equity for 2024:

	For the Three Months Ended March 31,	
	2026	2025
Gain on disposal of foreign listed shares	<u>\$ 12,232</u>	<u>-</u>

The amounts of income tax recognized in other comprehensive income for the three months ended March 31, 2026 and 2025 were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Items that will not be reclassified subsequently to profit or loss:		
Remeasurement from defined benefit plans	\$ -	-
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income	3,847	(4,352)
	<u>\$ 3,847</u>	<u>(4,352)</u>
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation	<u>\$ 167</u>	<u>(22)</u>

The Company's income tax returns for the years through 2024 were assessed by the Tax Administration.

(t) Capital and other equity

Except for the following disclosure, there was no significant change in capital and other equity for the periods from for the three months ended March 31, 2026 and 2025. For the related information, please refer to note (6)(v) to the consolidated financial statements for the year ended December 31, 2025.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1. Share capital

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Number of shares authorized (in thousands)	<u>200,000</u>	<u>200,000</u>	<u>200,000</u>
Shares authorized	<u>\$ 2,000,000</u>	<u>2,000,000</u>	<u>2,000,000</u>
Number of shares issued and fully paid (in thousands)	<u>188,367</u>	<u>171,567</u>	<u>163,398</u>
Shares issued	<u>\$ 1,883,674</u>	<u>1,715,674</u>	<u>1,633,975</u>

On November 7, 2025, the Board of Directors passed a resolution to issue 16,800 thousand shares of common stock for the capital increase in cash, with a par value of NTD10 per share, including 2,520 thousand shares subscribed by employees and 1,680 thousand shares for public offerings, at an issue price of \$ 60 per share. This capital increase was reported by the competent authority and took effect on December 22, 2025. The total cash subscription proceeds of \$1,080,000 thousand have been received in full. The base date of the capital increase is January 29, 2026. All relevant statutory registration procedures have been completed as of the reporting date.

The Company issued 8,170 thousand common shares amounting to \$81,699 thousand, with the date of capital increase set on September 9, 2025, based on the resolution decided during the shareholders' meeting held on June 26, 2025, and the approval of the Financial Supervisory Commission, R.O.C. on August 18, 2025. All relevant statutory registration procedures have been completed as of the reporting date.

A total of 10,000 thousand shares of the Company's authorized shares are reserved for the issuance of employee share options, convertible bonds with warrants and preferred shares with warrants.

2. Capital surplus

	<u>March 31,</u> <u>2026</u>	<u>December 31,</u> <u>2025</u>	<u>March 31,</u> <u>2025</u>
Additional paid-in capital arising from ordinary share	\$ 2,662,584	1,822,584	1,822,584
Additional paid-in capital arising from bond conversion	1,072,079	1,072,079	1,072,079
Difference between consideration and carrying amount of subsidiaries acquired or disposed	193,054	193,054	193,054
Changes in ownership interest in subsidiaries	250,941	250,941	250,872
Changes in equity of associates accounted for using equity method	8,315	8,315	339
Employee share options	18,152	-	-
Others	<u>43,860</u>	<u>43,860</u>	<u>43,860</u>
	<u>\$ 4,248,985</u>	<u>3,390,833</u>	<u>3,382,788</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Retained earnings

The Company's article of incorporation stipulates that Company's profit after tax should first be used to offset the prior years' deficits, including adjustment of unappropriated retained earnings and 10% of the rest be set aside as legal reserve, then the special surplus reserve shall be distributed or reversed according to the Laws acts and regulations approved by the Competent authority. The remainder, together with any undistributed retained earnings, including amount of adjusted retained earnings, shall be distributed by the Board of Directors and submitted to the stockholders' meeting for approval. The distribution of dividends, bonus, legal reserve and capital surplus, distributed by way of cash, shall be decided during the Board meeting, approved by more than half of the directors, with two thirds of directors in attendance; thereafter, to be submitted in the shareholders' meeting of the Company.

The Company's Articles also stipulate a dividend policy which is as follows: According to the present and future development plans, the investment environment, capital requirements, domestic and overseas competition, and the benefit of shareholders, the Company should distribute dividends and bonuses to shareholders at no less than 20% of the remaining profit (which is the current net profit less losses of previous years, less the adjustment to retained earnings, and less 10% of its after-tax annual earnings as legal reserve). Dividends could be distributed in cash or shares, where cash dividends should not be less than 20% of the total dividends distributed.

According to the amendment of the R.O.C. Company Act in January 2012, the Company must retain 10% of its after-tax annual earnings as legal reserve until such retention equals the amount of total capital. When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

The amount of cash dividends on the appropriations of earnings for 2025 and 2024 had been approved during the board meeting on March 6, 2026 and March 7, 2025. The amount of shares dividends of appropriation of earnings for 2024 has been approved during the shareholders' meeting on June 26, 2025, as follows:

	<u>2025</u>		<u>2024</u>	
	<u>Dividend per share (\$)</u>	<u>Amount</u>	<u>Dividend per share (\$)</u>	<u>Amount</u>
Dividends distributed to common shareholders				
Cash	\$ 4.30	809,980	3.80	620,910
Share	-	<u>-</u>	0.50	<u>81,699</u>
Total		<u><u>\$ 809,980</u></u>		<u><u>702,609</u></u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4. Other equity interest after tax

	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income
Balance as of January 1, 2026	\$ (43,667)	388,612
Exchange differences on translation of foreign financial statement	56,268	-
Unrealized losses from financial assets measured at fair value through other comprehensive income	(11,233)	(3,791)
Unrealized losses from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	(21,586)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	(16,620)
Balance as of March 31, 2026	<u>\$ 1,368</u>	<u>346,615</u>
Balance as of January 1, 2025	\$ (10,729)	344,217
Exchange differences on translation of foreign financial statement	44,619	-
Exchange differences on associates accounted for using equity method	(18,996)	-
Unrealized losses from financial assets measured at fair value through other comprehensive income	-	(14,142)
Unrealized gains from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	11,152
Balance as of March 31, 2025	<u>\$ 14,894</u>	<u>341,227</u>

5. Non-controlling interests after tax

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Balance, beginning of year	\$ 2,532,320	2,387,112
Shares attributed to non-controlling interests		
Net income	31,326	44,998
Exchange differences on translation of foreign financial statements	2,734	1,763
Unrealized gains or losses from financial assets measured at fair value through other comprehensive income	9,950	(10,026)
Change in equity of subsidiaries accounted for under equity method	2,912	-
Cash dividends of subsidiaries distributed to non controlling interests	(157,274)	(152,647)
Balance, end of year	<u>\$ 2,421,968</u>	<u>2,271,200</u>

(u) Share-based payments

On November 7, 2025, the Board of Directors passed a resolution to issue common stock for the capital increase in cash, and reserved a portion of the shares for employee subscription, with a par value of \$10 per share. The eligible recipients were limited to full-time employees of the Group and its subsidiaries who met specified conditions. This capital increase was reported by Financial Supervisory Commission R.O.C(Taiwan) and took effect.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1. Expense recognized in profit or loss and liabilities

The Group incurred expenses related to share-based payments for the three months ended March 31, 2026, as follows:

	For the Three Months Ended March 31, 2026
Expenses resulting from cash-settled share-based payment to employees	<u>\$ 21,064</u>

(v) Earnings per share

For the three months ended March 31, 2026 and 2025, the basic and diluted earnings per share were calculated as follows:

1. Basic earnings per share

	For the Three Months Ended March 31,	
	2026	2025
Profit attributable to ordinary shareholders of the Company	<u>\$ 205,180</u>	<u>195,243</u>
Weighted average number of ordinary shares (basic)(retroactive adjustments)	<u>183,141</u>	<u>163,398</u>

2. Diluted earnings per share

	For the Three Months Ended March 31,	
	2026	2025
Profit attributable to ordinary shareholders of the Company	<u>\$ 205,180</u>	<u>195,243</u>
Weighted average number of ordinary shares (basic)(retroactive adjustments)	183,141	163,398
Effect of employee stock compensation	635	541
Weighted average number of ordinary shares (diluted)(retroactive adjustments)	<u>183,776</u>	<u>163,939</u>

(w) Revenue from contracts with customers

1. Disaggregation of revenue

	For the Three Months Ended March 31,	
	2026	2025
Primary geographical markets:		
Taiwan	\$ 2,127,592	2,017,457
Hong Kong	3,515	1,054
China	875	7,036
Philippines	174,948	89,688
Malaysia	22,537	16,725
Indonesia	13,491	17,365
	<u>\$ 2,342,958</u>	<u>2,149,325</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	For the Three Months Ended March 31,	
	2026	2025
Major products:		
Product revenue		
Medical equipment and Supplies	\$ 1,386,895	1,220,572
Medicines	342,107	316,691
Aesthetic medical equipment and Supplies	241,051	257,834
Household appliances	37,192	34,790
Other	23,134	12,789
Repair and maintenance revenue	148,321	139,582
Other operating revenue	164,258	167,067
	\$ 2,342,958	2,149,325

2. Contract balances

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable, accounts receivable, lease payment receivable and other receivables	\$ 5,709,794	5,597,677	5,736,340
Less: allowance for impairment	(59,154)	(55,766)	(60,979)
Total	\$ 5,650,640	5,541,911	5,675,361
Contract liabilities	\$ 572,267	572,217	531,060

For details on trade receivables and allowance for impairment, please refer to note (6)(e).

The amount of revenue recognized for the three months ended March 31, 2026 and 2025 that was included in the contract liability balance at the beginning of the period were \$79,628 thousand and \$68,508 thousand, respectively.

(x) Employee compensation and directors' remuneration

On June 26, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Company Article of Incorporation, if the Company incurs profit for the year, the profit shall first be used to offset against any accumulated deficits. Thereafter, a maximum of 5% of the remaining net profit shall be allocated as directors' remuneration in cash, and no less than 1% (in shares or in cash) as employee remuneration. (At least 30% shall be allocated for salary adjustments or remuneration distributions for its non executive employees.) The distribution shall also include those employees of the Company's subsidiaries who meet certain requirements.

Prior to the amendment, the Articles of Incorporation stipulated that, if the Company incurs profit for the year, the profit shall first be used to offset against any accumulated deficits. Thereafter, a maximum of 5% of the remaining net profit shall be allocated as directors' remuneration in cash, and a minimum of 1% (in shares or in cash) as employee remuneration, including those employees of the Company's subsidiaries who meet certain requirements.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

For the three months ended March 31, 2026 and 2025, the Company estimated its employee compensation amounting to \$12,974 thousand and \$12,252 thousand, and directors' remuneration amounting to \$6,487 thousand and \$6,126 thousand, respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the compensation to employees and remuneration to directors of each period, multiplied by the percentage specified in the Company's articles. These remunerations were expensed under operating costs or expenses for each period. If there are any subsequent adjustments to the actual remuneration amounts after the annual shareholders' meeting, the adjustments will be regarded as changes in accounting estimates and will be reflected in profit or loss in the following year.

For the years ended December 31, 2025 and 2024, the compensation to employees which were paid in cash, amounted to \$50,271 thousand and \$47,985 thousand, respectively and directors' remuneration paid in cash, amounted to \$25,136 thousand and \$23,992 thousand, respectively. The information is available on the Market Observation Post System website.

(y) Non-operating income and expenses

1. Interest Income

The details of other income were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Interest income from bank deposits	\$ 11,148	18,989
Interest income from lease payment receivable	7,210	4,334
Total	\$ 18,358	23,323

2. Other income

The details of other income were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Dividend income	\$ 612	-
Other income	1,075	617
	\$ 1,687	617

3. Financial costs

The details of financial costs were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Bank borrowings	\$ 4,664	5,682
Others	3,389	2,900
	\$ 8,053	8,582

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4. Other gains and losses

The details of other gains and losses were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Gains (losses) on disposal of property, plant, and equipment	\$ 54	413
Foreign exchange (losses) gains	(2,554)	4,499
Net gains or losses on financial assets (liabilities) measured at fair value through profit or loss	454	1,261
Others	644	576
	\$ (1,402)	6,749

(z) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk arising from financial instruments. For related information, please refer to note (6)(z) to the consolidated financial statements for the year ended December 31, 2025.

1. Liquidity risks

The following are the contractual maturities of financial liabilities of the Group, including estimated interest payments and excluding the impact of netting arrangements:

	Carrying amount	Contractual cash flow	On Demand or Less than 1 month	1-3 months	3-6 months	6-12 months	1-2 years	More than 2 years
March 31, 2026								
Non-derivative financial liabilities								
Short-term borrowings	\$ 386,784	387,897	361,113	26,784	-	-	-	-
Payables	4,796,531	4,796,531	1,729,628	2,958,778	23,666	84,333	126	-
Lease liabilities	464,971	478,708	12,975	25,008	37,974	63,248	96,981	242,522
Long-term borrowings	350,000	482,868	583	1,166	1,748	3,497	6,993	468,881
Deposits received	9,580	9,580	-	-	-	-	-	9,580
Derivative financial liabilities								
Foreign exchange forward contracts:								
Outflows	18,907	18,907	-	18,907	-	-	-	-
Inflows	(19,102)	(19,102)	-	(19,102)	-	-	-	-
	\$ 6,007,671	6,155,389	2,104,299	3,011,541	63,388	151,078	104,100	720,983
December 31, 2025								
Non-derivative financial liabilities								
Short-term borrowings	\$ 1,343,221	1,344,055	950,236	393,819	-	-	-	-
Payables	3,742,683	3,742,683	819,879	2,797,534	38,303	86,967	-	-
Lease liabilities	460,685	462,806	12,224	23,547	35,334	70,347	91,710	229,644
Long-term borrowings	350,000	482,868	583	1,166	1,748	3,497	6,993	468,881
Deposits received	9,513	9,513	-	-	-	-	-	9,513
	\$ 5,906,102	6,041,925	1,782,922	3,216,066	75,385	160,811	98,703	708,038

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	<u>Carrying amount</u>	<u>Contractual cash flow</u>	<u>On Demand or Less than 1 month</u>	<u>1-3 months</u>	<u>3-6 months</u>	<u>6-12 months</u>	<u>1-2 years</u>	<u>More than 2 years</u>
March 31, 2025								
Non-derivative financial liabilities								
Short-term borrowings	\$ 518,257	518,308	50,051	468,257	-	-	-	-
Payables	5,229,157	5,229,157	1,503,741	3,604,008	41,588	79,820	-	-
Lease liabilities	483,098	502,182	12,203	23,626	33,949	65,304	114,649	252,451
Long-term borrowings	350,000	489,861	583	1,166	1,748	3,497	6,993	475,874
Deposits received	15,711	15,711	-	-	-	-	-	15,711
	<u>\$ 6,596,223</u>	<u>6,755,219</u>	<u>1,566,578</u>	<u>4,097,057</u>	<u>77,285</u>	<u>148,621</u>	<u>121,642</u>	<u>744,036</u>

The Group is not expecting that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

2. Market risks

1) Currency risks

The Group's significant exposure to foreign currency risk of financial assets and liabilities were as follows:

<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>March 31, 2026</u>	
			<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	32.011	USD	\$ 5,406	173,049
TWD	0.201	JPY	253,560	50,889
TWD	36.700	EUR	315	11,564
HKD	7.830	USD	1,486	47,563
USD	4.183	MYR	465	14,885
<u>Non-Monetary items</u>				
TWD	0.022	KRW	9,861,138	208,070
USD	0.031	TWD	791,055	791,055
USD	0.145	CNY	6,706	31,043
USD	0.128	HKD	293,296	1,198,935
USD	0.239	MYR	43,127	330,086

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

			March 31, 2026	
<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	0.201	JPY	336,582	67,552
TWD	32.011	USD	1,606	51,409
TWD	36.700	EUR	286	10,496
USD	60.765	PHP	2,760	88,350
			December 31, 2025	
<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	31.430	USD	\$ 3,647	114,622
TWD	0.201	JPY	63,280	12,706
HKD	4.038	USD	11,835	371,969
MYR	4.202	USD	573	18,010
<u>Non-Monetary items</u>				
TWD	0.022	KRW	10,415,732	229,146
USD	0.032	TWD	732,962	732,962
USD	0.143	CNY	6,747	30,326
USD	0.129	HKD	249,794	1,008,855
USD	0.238	MYR	43,086	322,296
USD	0.017	PHP	289,392	154,625
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	0.201	JPY	290,667	58,366
TWD	31.430	USD	1,590	49,973
PHP	58.913	USD	1,769	55,600

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>Functional currency</u>	<u>Exchange rate</u>	<u>Currency</u>	<u>March 31, 2025</u>	
			<u>Foreign currency (in thousands)</u>	<u>Carrying amount (TWD)</u>
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	33.205	USD	\$ 13,607	451,818
TWD	0.223	JPY	69,824	15,550
TWD	35.970	EUR	451	16,226
HKD	7.780	USD	1,567	52,027
MYR	4.599	USD	344	11,423
<u>Non-Monetary items</u>				
TWD	0.024	KRW	4,321,125	98,392
USD	0.030	TWD	712,052	712,052
USD	0.138	CNY	6,803	31,106
USD	0.129	HKD	244,454	1,043,047
USD	0.217	MYR	44,406	320,560
USD	0.018	PHP	193,193	112,262
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	0.223	JPY	339,099	75,517
TWD	33.205	USD	1,434	47,615
PHP	57.240	USD	848	28,158

Since the Group has many kinds of currency, the information on foreign exchange gains or losses on monetary items is disclosed by total amount. For the three months ended March 31, 2026 and 2025, foreign exchange gains or losses amounted to losses of \$2,554 thousand and gains of \$4,499 thousand, respectively.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Sensitivity analysis

The Group's foreign exchange exposure to foreign currency risk arises from foreign currency exchange fluctuations on cash and cash equivalents, accounts receivables and accounts payables. Assuming other variables remain the same, a 1% depreciation or appreciation of the TWD against foreign currency as of March 31, 2026 and 2025 would have increased or decreased the net profit after tax by \$592 thousand and \$2,893 thousand, respectively. The analysis is performed on the same basis for both periods.

3) Interest rate risk

The Group's financial assets and financial liabilities with interest rate exposure risk were noted in the liquidity risk section.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding liabilities with variable interest rates, the analysis is based on the assumption that the amount of liabilities outstanding at the reporting date was outstanding throughout the year.

If the interest rate increases or decreases by 1%, assuming that all other variables remain constant, the Group's net profit after tax will increase or decrease by \$10,509 thousand and \$11,654 thousand for the three months ended March 31, 2026 and 2025, respectively. The changes are mainly due to floating rate bank deposits and borrowings of the Group.

4) Other price risks

Assuming that the analysis is performed on the same basis for both periods, if equity prices had been 1% higher/lower, pre-tax other comprehensive income for the three months ended March 31, 2026 and 2025 would have increased/decreased by \$8,414 thousand and \$6,274 thousand, respectively, as a result of the changes in fair values of financial assets at fair value through other comprehensive income.

3. Fair value information

1) The categories and fair values of financial instruments

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	March 31, 2026				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Derivative financial assets	\$ 28	-	28	-	28
Financial assets at fair value through other comprehensive income					
Domestic listed shares	24,643	24,643	-	-	24,643
Foreign listed shares	230,809	230,809	-	-	230,809
Domestic unlisted shares	123,329	-	-	123,329	123,329
Foreign unlisted shares	462,654	-	-	462,654	462,654
Sub-total	841,435	255,452	-	585,983	841,435
Financial assets at amortized cost					
Cash and cash equivalents	3,077,674	-	-	-	-
Time deposits with original maturity of more than 3 months	658,830	-	-	-	-
Receivables	5,650,640	-	-	-	-
Guarantee deposits paid	267,244	-	-	-	-
Other financial assets	113,338	-	-	-	-
Sub-total	9,767,726	-	-	-	-
Total	\$ 10,609,189	255,452	28	585,983	841,463
Financial liabilities at fair value through profit or loss					
Derivative financial liabilities	\$ 195	-	195	-	195
Financial liabilities at amortized cost					
Short-term and long-term borrowings	736,784	-	-	-	-
Payables	4,796,531	-	-	-	-
Guarantee deposits received	9,580	-	-	-	-
Lease liabilities	464,971	-	-	-	-
Sub-total	6,007,866	-	-	-	-
Total	\$ 6,008,061	-	195	-	195

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	December 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed shares	\$ 2,659	2,659	-	-	2,659
Foreign listed shares	248,855	248,855	-	-	248,855
Domestic unlisted shares	132,312	-	-	132,312	132,312
Foreign unlisted shares	497,648	-	-	497,648	497,648
Accounts receivable	<u>3,581</u>	-	-	-	-
Sub-total	<u>885,055</u>	<u>251,514</u>	<u>-</u>	<u>629,960</u>	<u>881,474</u>
Financial assets at amortized cost					
Cash and cash equivalents	2,847,128	-	-	-	-
Time deposits with original maturity of more than 3 months	612,160	-	-	-	-
Receivables	5,541,911	-	-	-	-
Guarantee deposits paid	282,019	-	-	-	-
Other financial assets	<u>112,685</u>	-	-	-	-
Sub-total	<u>9,395,903</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 10,280,958</u>	<u>251,514</u>	<u>-</u>	<u>629,960</u>	<u>881,474</u>
Financial liabilities at amortized cost					
Short-term and long-term borrowings	\$ 1,693,221	-	-	-	-
Payables	3,742,683	-	-	-	-
Guarantee deposits received	9,513	-	-	-	-
Lease liabilities	<u>460,685</u>	-	-	-	-
Total	<u>\$ 5,906,102</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	March 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed shares	\$ 2,537	2,537	-	-	2,537
Foreign listed shares	106,064	106,064	-	-	106,064
Domestic unlisted shares	144,260	-	-	144,260	144,260
Foreign unlisted shares	<u>374,571</u>	<u>-</u>	<u>-</u>	<u>374,571</u>	<u>374,571</u>
Sub-total	<u>627,432</u>	<u>108,601</u>	<u>-</u>	<u>518,831</u>	<u>627,432</u>
Financial assets at amortized cost					
Cash and cash equivalents	2,796,669	-	-	-	-
Time deposits with original maturity of more than 3 months	600,480	-	-	-	-
Receivables	5,675,361	-	-	-	-
Guarantee deposits paid	168,309	-	-	-	-
Other financial assets	<u>125,495</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Sub-total	<u>9,366,314</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 9,993,746</u>	<u>108,601</u>	<u>-</u>	<u>518,831</u>	<u>627,432</u>
Financial liabilities at amortized cost					
Short-term and long-term borrowings	\$ 868,257	-	-	-	-
Payables	5,229,157	-	-	-	-
Guarantee deposits received	15,711	-	-	-	-
Lease liabilities	<u>483,098</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 6,596,223</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

2) Valuation techniques for financial instruments not measured at fair value

The Group's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

A. Financial assets measured at amortized cost

If the quoted prices in active markets are available, the market price is established as the fair value. However, if quoted prices in active markets are not available, the estimated valuation or prices used by competitors are adopted.

B. Financial liabilities measured at amortized cost

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimated fair values.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3) Valuation techniques for financial instruments measured at fair value

The Group considers the financial status, operating analysis, most recent transaction price, non-active market quoted price of related equity instrument, and active-market quoted price of similar instrument, and other information, in determining the input value of its investee companies. Periodically updates of information and input value for the valuation model and any necessary adjustments of fair value are required to ensure that the results of estimation are reasonable.

A. Non-derivative financial instruments

If quoted prices in active markets are available, the prices are established as fair values, such as public quoted company stock.

For the Group's financial instruments that have no active markets, the measurement of fair values is listed as follows:

Equity instrument that has no quoted price: The method of comparable Listed Company approach is used to estimate the fair value. The main assumption for the method is to determine the fair value by using the transaction price paid for an identical or a similar instrument of an investee.

B. Derivative financial instruments

Derivative financial instruments are measured by using the common valuation models such as discounted cash flow model and Black-Scholes model.

4) Changes in level 3 of the fair value

	<u>Fair value through other comprehensive income</u> <u>unquoted equity instruments</u>
Balance as of January 1, 2026	\$ 629,960
Total gains and losses recognized	
In other comprehensive income	(43,954)
Reclassification and effect of movements in exchange rates	<u>(23)</u>
Balance as of March 31, 2026	<u>\$ 585,983</u>
Balance as of January 1, 2025	\$ 532,469
Total gains and losses recognized	
In other comprehensive income	(13,965)
Reclassification and effect of movements in exchange rates	<u>327</u>
Balance as of March 31, 2025	<u>\$ 518,831</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

For the three months ended March 31, 2026 and 2025, the total gains and losses that were included in “unrealized gains and losses from financial assets at fair value through other comprehensive income” were as follows:

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Total gains and losses recognized		
In other comprehensive income, and presented in “unrealized gains and losses from financial assets at fair value through other comprehensive income”	\$ (43,954)	(13,965)

5) Quantified information for significant unobservable inputs (level 3) used in fair value measurement

The Group’s financial instruments that use Level 3 inputs to measure fair value include “financial assets at fair value through other comprehensive income— equity investments without active market”.

Quantified information of significant unobservable inputs was as follows:

<u>Item</u>	<u>Valuation techniques</u>	<u>Significant non-observable inputs</u>	<u>The relationship between significant Non-observable inputs and fair value</u>
Financial assets at fair value through other comprehensive income - equity instruments investments without an active market	Market approach- Company comparisons	<ul style="list-style-type: none"> · P/B Value Multiple (0.674~2.54, 0.746~2.91 and 0.72~2.14 as of March 31, 2026、December 31, 2025 and March 31, 2025, respectively.) · Discount due to Lack of Market liquidity (12.31%~30%, 12.93%~30% and 9.49%~30% as of March 31, 2026、December 31, 2025 and March 31, 2025, respectively.) 	· The estimated fair value would increase (decrease) if the value multiple is higher (lower) and the marketability discount is lower (higher)

6) Sensitivity analysis for fair values of financial instruments using Level 3 Inputs

The Group’s fair value measurement on financial instruments is reasonable. However, the measurement would differ if different valuation models or valuation parameters are used. For financial instruments using level 3 inputs, if the valuation parameters are changed, the impact on net income or loss and other comprehensive income or loss will be as follows:

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	Input	Variation	Impact on Fair Value Change on Other Comprehensive income or loss	
			Favorable Change	Unfavorable Change
March 31, 2026				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 28,384	(28,384)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	39,267	(39,267)
			<u>\$ 67,651</u>	<u>(67,651)</u>
December 31, 2025				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 30,654	(30,654)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	42,391	(42,391)
			<u>\$ 73,045</u>	<u>(73,045)</u>
March 31, 2025				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 25,117	(25,117)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	33,999	(33,999)
			<u>\$ 59,116</u>	<u>(59,116)</u>

(aa) Financial risk management

There were no significant differences of the Group's financial risk management and policies with those disclosed in Note (6)(z) of the consolidated financial statements for the year ended December 31, 2025.

(ab) Capital Management

Management believes that the objectives, policies and processes of capital management of the Group have been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2025. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2025. Please refer to note (6)(aa) to the consolidated financial statement for the year ended December 31, 2025 for further details.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(ac) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow in the three months ended March 31, 2026 and 2025, were as follows:

For acquisitions of right-of-use assets by leasing, please refer to note 6(j).

Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2026	Cash flows	Non-cash changes			March 31, 2026
			Acquisition	Foreign exchange movement	Others	
Short-term and long-term borrowings	\$ 1,693,221	(956,437)	-	-	-	736,784
Lease liabilities	460,685	(36,498)	45,653	(545)	(4,324)	464,971
Total liabilities from financing activities	<u>\$ 2,153,906</u>	<u>(992,935)</u>	<u>45,653</u>	<u>(545)</u>	<u>(4,324)</u>	<u>1,201,755</u>

	January 1, 2025	Cash flows	Non-cash changes			March 31, 2025
			Acquisition	Foreign exchange movement	Others	
Short-term and long-term borrowings	\$ 917,531	(49,274)	-	-	-	868,257
Lease liabilities	506,170	(33,467)	9,856	573	(34)	483,098
Total liabilities from financing activities	<u>\$ 1,423,701</u>	<u>(82,741)</u>	<u>9,856</u>	<u>573</u>	<u>(34)</u>	<u>1,351,355</u>

(7) Related Party Transactions

(a) Names of related parties and their relationship with related parties

The followings are related parties that have had transactions with the Group during the periods covered in the consolidated financial statements.

<u>Name of related party</u>	<u>Relationship with the Group</u>
Excelsior Investment Co., Ltd.	Entities with significant influence over the Group
Excelsior Group Holdings Co., Ltd.	//
Xuan Hui Co., Ltd.	//
Bestchain Healthtaiwan Co., Ltd. (Bestchain)	Associate
Excelsior Renal Service Co., Limited (ERS)	//
Asia Best Healthcare Co., Limited (ABH)	//
Medifly Co., Ltd.	//
Asia Best Life Care Co., Ltd. (ABL)	//
Excelsior Long Term Care Corporation Entity	//
Medytox Taiwan Inc.	//
Touce Biotech Co., Ltd. (Touce Biotech)	//
Bestsmile Co., Ltd.(Bestsmile)	//

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>Name of related party</u>	<u>Relationship with the Group</u>
Exceed Healthcare Co., Ltd.	Associate
Anxin Nice Care Co., Ltd.	//
NephroCare Limited	//
Cardinal Medical Services Ltd.	//
Excelsior Health Foundation	Other related parties

(b) Significant transactions with related parties

1. Operating revenue

1) Sales revenue

The amounts of significant sales by the Group to related parties were as follows:

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Associate – Bestchain	\$ 652,738	601,795
Associate – ERS	190,899	183,578
Associate – Others	54,526	65,009
Other related parties	-	33
	<u>\$ 898,163</u>	<u>850,415</u>

The aforementioned transactions, except the sales to Bestchain and ERS that were priced on a cost-plus basis, were conducted on normal commercial terms.

2) Repair and maintenance revenue

The amounts of significant repair and maintenance revenue by the Group to related parties were as follows:

	<u>For the Three Months Ended March 31,</u>	
	<u>2026</u>	<u>2025</u>
Associate – ERS	\$ 22,963	23,018
Associate – Bestchain	1,501	2,772
Associate – Others	-	194
	<u>\$ 24,464</u>	<u>25,984</u>

There were no significant differences in the terms and pricing offered to related parties compared with those offered to third parties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3) Other operating revenue-rental revenue

The amounts of significant other operating revenue-rental revenue by the Group to related parties were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Entities with significant influence over the Group	\$ 18	18
Associate – ABH	8,541	6,481
Associate – ERS	1,085	1,174
Associate – Others	706	5,156
Other related parties	11	11
	\$ 10,361	12,840

The aforementioned transactions, except that the rental amounts were based on mutual agreements, all other terms were based on standard conditions.

4) Other operating revenue-service revenue

The amounts of significant other operating revenue-service revenue by the Group to related parties were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Associate	\$ 3,017	3,886
Other related parties	66	62
	\$ 3,083	3,948

There were no significant differences in the terms and pricing offered to associates compared with those offered to third parties.

2. Purchases from related parties

The amounts of significant purchases by the Group from related parties were as follows:

	For the Three Months Ended March 31,	
	2026	2025
Associate	\$ 36,847	54,499

There were no significant differences in terms and conditions of the purchases from associates between those provided to the third parties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3.Receivables from related parties

Receivables from related parties were as follows:

<u>Accounted for as</u>	<u>Category of related party</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Notes receivable	Associate	\$ 36	29	21
Other notes receivable	Associate	1,085	916	1,398
Accounts receivable	Associate— Bestchain	689,178	663,255	635,645
Accounts receivable	Associate— ERS	155,666	161,750	151,673
Accounts receivable	Associate— Others	46,127	55,001	51,068
Accounts receivable	Other related parties	128	62	62
Other receivables	Associate	4,062	2,097	2,392

4.Payables to related parties

Payables to related parties were as follows:

<u>Accounted for as</u>	<u>Category of related party</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Accounts payable	Associate	\$ 8,997	24,824	26,973
Other payables	Associate	14,723	16,053	10,577
Deposits received	Associate	7,891	7,891	12,263

5.Prepayments

Prepayments to related parties were as follows:

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Associate	\$ <u>4,278</u>	<u>10,967</u>	<u>26,737</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

6. Property transactions

1) Purchases of property, plant and equipment

The purchases price of property, plant and equipment purchased from related parties are summarized as follows:

	For the Three Months Ended March 31,	
	2026	2025
Associate – ABL	\$ <u>3,817</u>	<u>-</u>

7. Guarantee

As of March 31, 2026, December 31, 2025 and March 31, 2025, the Group provided associates guarantees for loans. The credit limit of the guarantees were \$800,000 thousand, \$1,200,000 thousand and \$800,000 thousand, and the amount utilized were \$350,000 thousand, \$200,000 thousand and \$335,000 thousand, respectively.

8. Capital and Equity

For future planning purposes, the Group increased its investment in Associates - Medytox Taiwan Inc. by NT\$8,000 thousand in 2025, with no change in its ownership percentage after the capital injection.

9. Others

	For the Three Months Ended March 31,	
	2026	2025
<u>Associates and Other related parties</u>		
Other revenue	\$ 787	496
Cost of goods sold	(1,125)	(4,566)
Repair and maintenance costs	(489)	(1,038)
Fright and warehousing expense	(13,209)	(13,080)
Rent expense	(452)	(1,385)
Other expense	(8,400)	(7,444)

The aforementioned rentals collected or paid quarterly or monthly were based on prevailing market rates.

As of March 31, 2026, December 31, 2025 and March 31, 2025, the Group had received collections in advance from associates for \$2,910 thousand, \$1,292 thousand and \$858 thousand, respectively.

(c) Key management personnel compensation

Key management personnel compensation comprised:

	For the Three Months Ended March 31,	
	2026	2025
Short-term employee benefits	\$ 21,941	21,925
Post-employment benefit	176	251
Share-based payment	9,761	-
	<u>\$ 31,878</u>	<u>22,176</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(8) Pledged Assets

The carrying amount of pledged assets were as follows:

<u>Pledged assets</u>	<u>Object</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Current deposits and time deposits	Bank loans, bank guarantee and credit card document receiving service guarantee	\$ 113,338	109,646	123,434
Notes receivable and other notes receivable	Guarantee of short-term loan or strengthening credit	259,047	197,298	323,417
Property, plant and equipment	Bank loans	101,689	99,403	95,936
Investment property	"	1,345,371	1,346,530	1,354,985
Refundable deposits (Recognized in other non-current financial assets)	Guarantees for sales performance, deposits and lease deposits, etc.	263,996	282,019	168,309
		<u>\$ 2,083,441</u>	<u>2,034,896</u>	<u>2,066,081</u>

(9) Significant Commitments and Contingencies

(a) Unrecognized contractual commitments

1. As of March 31, 2026, December 31, 2025 and March 31, 2025, the unused letters of credit were \$65,539 thousand, \$54,634 thousand and \$87,169 thousand, respectively. The guarantee letters issued by banks for sales contract guarantee and purchase bid of hospital were \$1,073,687 thousand, \$1,054,975 thousand and \$923,310 thousand, respectively.
2. In April 2022, the Company entered into a supply agreement with the Hong Kong-based company. Pursuant to the agreement, the Company shall purchase certain products from the Hong Kong-based company in agreed quantities at agreed prices annually.
3. The Group won the bid for the procurement project for COVID-19 treatment drugs (including storage and distribution) from the Centers for Disease Control, Ministry of Health and Welfare (CDC), who entered into an agreement with the Group on July 17, 2024, in which the Group will purchase drugs and provide storage and distribution services to the CDC.
4. On November 7, 2025, the Board of Directors approved the plan to enter into a warehouse lease agreement with its related party, Bestchain Healthtaiwan Co., Ltd., in consideration of future operational requirements and business development. The total contract amount is NT\$99,500 thousand.

(10) Losses due to Major Disasters : None.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(11) Subsequent Events

A resolution was approved during the Company's board meeting held on November 7, 2025 for the Group to acquire of righ-of-use assets amount of NT\$99,253 thousand. On December 2025 the Group sign a warehouse lease agreement with its associate, Bestchain Health Taiwan Co., Ltd., with a leasing period from May 4, 2026 to May 3, 2028.

(12) Other

- (a) The employee benefits, depreciation, depletion and amortization expenses categorized by function were as follows:

By function By item	For the Three Months Ended March 31, 2026			For the Three Months Ended March 31, 2025		
	Operating cost	Operating expense	Total	Operating cost	Operating expense	Total
Employee benefits						
Salary	81,193	153,846	235,039	70,923	137,596	208,519
Labor and health insurance	8,099	12,863	20,962	7,651	12,011	19,662
Pension	3,959	6,251	10,210	3,567	5,816	9,383
Others	3,806	7,024	10,830	3,732	6,241	9,973
Depreciation	50,953	21,362	72,315	56,933	18,560	75,493
Amortization	10	2,076	2,086	174	1,612	1,786

(13) Other disclosures

- (a) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group for the three months ended March 31, 2026:

1. Fund financing to other parties: None.
2. Guarantees and endorsements for other parties:

(Expressed in thousands of New Taiwan dollars)

No.	Endorsement/guarantee provider	Counter-party		Limitation on endorsement/guarantee amount provided to each guaranteed party	Maximum balance for the year	Ending balance	Amount actually drawn	Amount of endorsement/guarantee collateralized by properties	Ratio of accumulated endorsement/guarantee to net equity per latest financial statements	Maximum endorsement/guarantee amount allowance (Note 7)	Guarantee provided by parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Name	Nature of relationship (Note 2)										
0	The Company	Excelsior Asset Management CO., Ltd. (Note 4)	2	1,926,659	990,000	570,000	-	-	5.92 %	9,633,296	Y	N	N
0	"	EG Healthcare, Inc. (Note 4)	2	1,926,659	122,373	122,373	-	-	1.27 %	9,633,296	Y	N	N
0	"	Renal Laboratories Sdn. Bhd. (Note 4)	2	1,926,659	80,028	80,028	26,784	-	0.83 %	9,633,296	Y	N	N

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

No.	Endorsement/guarantee provider	Counter-party		Limitation on endorsement/guarantee amount provided to each guaranteed party	Maximum balance for the year	Ending balance	Amount actually drawn	Amount of endorsement/guarantee collateralized by properties	Ratio of accumulated endorsement/guarantee to net equity per latest financial statements	Maximum endorsement/guarantee amount allowance (Note 7)	Guarantee provided by parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Name	Nature of relationship (Note 2)										
0	The Company	Medi-Chem System Sdn. Bhd. (Note 4)	2	1,926,659	16,005	16,005	-	-	0.17 %	9,633,296	Y	N	N
0	"	Bestchain Healthtaiwan Co., Ltd. (Note 3)	1	2,464,263	1,200,000	800,000	350,000	-	8.30 %	9,633,296	N	N	N
1	Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc. (Note 5)	2	315,794	200,000	100,000	-	-	6.33 %	789,484	Y	N	N
2	Dynamic Medical Technologies Inc.	Arich Enterprise Co., Ltd. (Note 6)	3	9,432	-	-	-	-	- %	15,721	N	Y	N

Note 1: the description of number column:

1. 0 is issuer.
2. Investees are listed by name and numbered starting with 1.

Note 2: Relationship with the Company

1. The companies with which it has business relations.
2. Subsidiaries in which the Company directly or indirectly holds more than 50% of its total outstanding common shares.
3. The parent company which directly or indirectly holds more than 50% of its voting rights.
4. Subsidiaries in which the Company directly or indirectly holds more than 90% of its voting rights.
5. Companies in the same type of business and providing mutual endorsements/ guarantees in favor of each other in accordance with the contractual obligations in order to fulfill the needs of the construction project.
6. Shareholders making endorsements and/or guarantees for their mutually invested company in proportion to their shareholding percentage.
7. Companies in the same type of business providing guarantees of pre-sale contracts according to the regulation.

Note 3: For guarantee and endorsement to those companies with business contact, the maximum amount cannot exceed the trading amount between two parties for the current year.

Note 4: The total amount of guarantee and endorsement cannot exceed 20% of the Company's net asset value from the most recent audited or reviewed report.

Note 5: The total amount of guarantee and endorsement cannot exceed 20% of Dynamic's net asset value from the most recent audited or reviewed report.

Note 6: The total amount of guarantee and endorsement cannot exceed 30% of Arich Best Chain's net asset value from the most recent audited or reviewed report.

Note 7: The total amount of guarantee and endorsement cannot exceed the Company's net asset value from the most recent audited or review report: Dynamic and Arich Best Chain cannot exceed 50% of its net asset value from the most recent audited or reviewed report.

3. Information regarding material securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(Expressed in thousands of New Taiwan dollars)

Name of holder	Category and name of security	Relationship with the Company	Account title	Ending balance			Market value	Notes
				Number of shares	Book value	Percentage of shares		
The Company	3-D Matrix, Ltd.	-	Fair value through other comprehensive income	273,400	22,936	0.22 %	22,936	
"	Gie Cheng Co., Ltd.	-	"	3,795,000	28,918	17.25 %	28,918	
"	Rui Guang Healthcare Co., Ltd.	-	"	2,423,951	28,312	7.15 %	28,312	
"	Sunder Biomedical Tech. Co., Ltd.	-	"	2,279,578	47,734	3.80 %	47,734	
"	Linkon International Golf & Country Club	-	"	1	16,100	0.10 %	16,100	
"	Chi Sheng Pharma & Biotech Co., Ltd.	-	"	848,300	24,643	1.42 %	24,643	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of holder	Category and name of security	Relationship with the Company	Account title	Ending balance				Notes
				Number of shares	Book value	Percentage of shares	Market value	
Excelsior Healthcare Co. Limited	Chai Tai Bo Ai Investment Limited	-	Fair value through other comprehensive income	10,000	-	8.00 %	-	
EG Healthcare, Inc.	The Orchard Golf & Country Club	-	"	1	2,060	- %	2,060	
Dynamic Medical Technologies Inc.	Caregen Co., Ltd.	-	"	108,500	207,873	0.20 %	207,873	
Excelsior Beauty Co., Ltd.	Join Fun Co., Ltd.	-	"	263,340	2,265	19.00 %	2,265	
Arich Enterprise Co., Ltd.	National Pharmaceutical Logistics Corp., Ltd.	Board director of investee	"	-	460,594	17.65 %	460,594	Note

Note : Act as limited company, no outstanding share.

4. Information regarding related-party purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of company	Name of Counter-party	Relationship	Transaction details				Transactions with terms different from others		Account/note receivable (payable)		Notes
			Purchase/Sale	Amount	Percentage of total purchases/sales	Credit period	Unit price	Credit period	Balance	Percentage of total accounts/notes receivable (payable)	
The Company	Excelsior Renal Service Co., Limited	Associates	Sales	190,896	(13.85)%	Net 30-60 days	-	-	155,666	11.28 %	Note 1
"	Bestchain Healthtaiwan Co., Ltd.	"	"	652,486	(47.35)%	Net 30-90 days	-	-	688,866	49.93 %	Note 1

Note 1: The unit price of cost of goods sold for the Company is based on cost-plus pricing approach by product that is lower than average; because, the expense of goods sold for related parties is lower than average price as well.

5. Information regarding receivables from related parties exceeding 100 million or 20% of the Company's paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of related party	Counter-party	Relationship	Balance of receivables from related party	Turnover rate	Past-due receivables from related party		Subsequently received amount of receivables from related party	Allowances for bad debts
					Amount	Action taken		
The Company	Excelsior Renal Service Co., Limited	Associates	155,666	4.81	-	-	60,259	-
"	Bestchain Healthtaiwan Co., Ltd.	"	652,486	3.86	-	-	-	-

6. Significant transactions and business relationship between the parent company and its subsidiaries for the three months ended March 31, 2026:

Number	Name of the company	Name of the counter-party	Existing relationship with the counter-party	Transaction details during 2026			Percentage of the total consolidated revenue or total assets
				Account name	Amount	Terms of trading	
0	The Company	EG Healthcare, Inc.	1	Sales	55,656	Usual terms and conditions	2.38 %
"	"	"	1	Account Receivable	83,105	The same as the term for other general trading partners	0.43 %
1	Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc.	3	Account Receivable	43,809	The same as the term for other general trading partners	0.22 %
"	"	"	3	Sales	19,669	Base on cost-plus pricing	0.84 %

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Note 1: The numbers denote the following:

1. 0 represents the Company.
2. Subsidiaries are listed by names and numbered starting with 1.

Note 2: Relationship with the listed companies:

1. The Company to subsidiary
2. Subsidiary to the Company
3. Subsidiary to subsidiary

Note 3: The transaction amount is calculated as a proportion of the consolidated revenue or assets. If categorized as an asset or liability, the calculation is compared with the consolidated assets; if categorized as income or loss, the calculation is compared with the consolidated income or loss.

Note 4: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(b) Information on investees:

For the three months ended March 31, 2026, the following is the information of investees (excluding investees in Mainland china):

(Amounts Expressed in Thousands of New Taiwan Dollars, Except for Share Data)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value			
The Company	Bestchain Healthtaiwan Co., Ltd.	New Taipei City	Sale of medical equipment and medicines, interagation of warehousing and information	299,024	299,024	65,730,352	44.71 %	1,114,573	32,863	14,674	Associates (Note 1)
"	Arich Enterprise Co., Ltd.	New Taipei City	Sale of medicines, and logistics service	380,856	380,856	29,829,742	40.00 %	768,326	19,175	7,670	Subsidiary (Note 2)
"	Dynamic Medical Technologies Inc.	New Taipei City	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	116,131	116,131	13,563,450	33.97 %	547,372	33,413	11,350	Subsidiary
"	Excelsior Healthcare Co., Limited	British Virgin Islands	Investment business	898,782	898,782	28,695,856	100.00 %	1,917,345	69,089	69,089	Subsidiary
"	Sunrise Health Care Company	New Taipei City	Sale of medical equipment, and medical management consultancy service	18,806	18,806	2,085,547	20.86 %	28,200	357	74	Associates
"	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	963,137	963,137	33,807,013	64.36 %	1,321,766	34,781	22,385	Subsidiary
"	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	28,543	28,543	5,190,662	41.02 %	96,811	10,300	4,225	Sub-subsiidiary
"	Excelsior Asset Management Co., Ltd.	New Taipei City	Sales of medical equipment, precision instrument and real estate	780,525	780,525	87,375,600	100.00 %	726,009	8,692	8,692	Subsidiary
"	Medifly Co., Ltd.	Taichung	Sale of medical equipment and medicines	31,899	31,899	3,615,976	28.66 %	104,402	11,088	3,178	Associates
"	Asia Best Life Care Co., Ltd	New Taipei City	Long-term care and rehabilitation services, rental and leasing services, medical consumables sales and information service	953,836	953,836	84,633,340	49.02 %	1,054,192	38,287	18,768	Associates

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value			
Excelsior Healthcare Co., Limited	EG Healthcare, Inc.	Philippines	Sale and lease of medical equipment, and medical management consultancy service	82,166	19,256	9,427,489	99.99 %	173,842	21,047	-	
"	Excelsior Renal Service Co., Limited	Hong Kong	Sale, maintenance and lease of medical equipment, and medical management consultancy service	312,505	312,505	73,375,728	49.00 %	447,653	68,872	-	Associates
"	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	516,071	516,071	18,724,062	35.64 %	731,941	34,781	-	Subsidiary
"	Excelsior Investment (Malaysia) Co., Ltd	British Virgin Islands	Investment business	343,026	343,026	11,171,272	100.00 %	330,086	383	-	Sub-subsiary
Dynamic Medical Technologies Inc.	Dynamic Medical Technologies (Hong Kong) Ltd.	Hong Kong	Sale of cosmetic health-care products	104,652	104,652	13,061,783	100.00 %	59,409	(268)	-	Sub-subsiary
"	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	55,395	55,395	6,819,523	53.89 %	121,016	10,300	-	Sub-subsiary (Note 1)
"	CYJ International Taiwan Inc.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	155,709	155,709	13,851,588	55.41 %	143,522	(6,624)	-	Sub-subsiary
"	Medytox Taiwan Inc.	Taipei City	Sale of cosmetic health-care products	26,000	26,000	2,600,000	40.00 %	6,358	1,471	-	Associates
"	TOUCE BIOTECH Co., Ltd	New Taipei City	Sale of cosmetic health-care products	45,000	45,000	420,000	35.00 %	45,875	1,163	-	Associates
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd.	New Taipei City	Logistics Bussiness	31,080	31,080	3,000,000	100.00 %	32,496	257	-	Sub-subsiary
Excelsior Medical (HK) Co., Limited	Asia Best Healthcare Co., Ltd.	Cayman Islands	Healthcare managment services	458,902	458,902	129,492	48.47 %	653,413	12,338	-	Associates
"	Cardinal Medical Services Ltd.	British Virgin Islands	Sale of medical equipment, and medical management consultancy service	106,121	106,121	9,800	49.00 %	136,648	26,460	-	Associates
"	NephroCare Limited	Hong Kong	Sale of medical equipment, and medical management consultancy service	688,755	688,755	151,801,588	49.00 %	751,282	24,368	-	Associates
Excelsior Investment (Malaysia) Co., Ltd	Renal Laboratories Sdn. Bhd.	Malaysia	Manufacture of medical equipment	288,387	288,387	32,523,586	81.90 %	282,727	439	-	Sub-subsiary
"	Medi-Chem Systems Sdn. Bhd.	Malaysia	Sale of medical equipment	44,052	44,052	350,000	70.00 %	42,123	573	-	Sub-subsiary
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Malaysia	Lease business	1,315	1,315	200,000	100.00 %	9,799	18	-	Sub-subsiary

Note 1: Including the adjustment made from the unrealized gain/loss with subsidiaries and associates.

Note 2: Including the amortization listed by the book value of net identified assets.

Note 3: On November 25, 2025, the Board of Directors of EG Healthcare, Inc. approved a cash capital increase of \$1,672,503, at an issue price of USD 2,000 thousand per share. Following the capital increase, which were fully subscribed by the Group. This capital increase has been changed on March 27, 2026.

Note 4: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Information on investment in Mainland China:

1. Information on investment in Mainland China:

(Amounts Expressed in Thousands of New Taiwan Dollars)

Name of the investee	Main Businesses and products	Total amount of pain-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2026	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2026	Net income (loss) of the investee	Direct /indirect shareholding (%) by the Company	Current investment gains and losses	Carrying Amount	Accumulated Inward Remittance of Earnings
					Out-flow	Inflow						
Excelsior Healthcare (Shanghai) Corporation (Note 3)	Sale and lease of medical equipment, and medical management consultancy service	-	(2)	30,240	-	-	30,240	-	- %	-	-	-
Shanghai Lintech Medicare Co. (Note 4)	Sale and maintenance of medical equipment	-	(2)	29,213	-	-	29,213	-	- %	-	-	-
Pacific Beijing Bo-Ai Medical Management Consulting Co., Ltd.	Investment business and medical management consultancy service	84,187	(2)	80,327	-	-	80,327	88	7.80 %	-	-	-
SinoExcelsior Investment Inc. (Note 5, 7)	Sale of medical equipment, and medical management consultancy service	179,004	(2)	947,845	-	-	947,845	(185)	100.00 %	(185)	31,043	-
Guangzhou Dynamic Inc.	Sale and maintenance of medical equipment	44,346	(2)	119,574	-	-	119,574	(335)	100.00 %	(335)	6,984	-
Beijing Dynamic Inc. (Note 6)	Sale and maintenance of medical equipment	-	(2)	7,101	-	-	7,101	-	- %	-	-	-
National Pharmaceutical Logistics Corp., Ltd.	Medical logistics	370,493	(3)	66,603	-	-	66,603	17,149	17.65 %	-	460,594	93,846

2. Limitation on investment in Mainland China:

Company	Accumulated Investment in Mainland China as of December 31, 2026	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment (Note 8)
The Company	1,087,625	1,289,640	5,779,978
Dynamic Medical Technologies Inc.	126,675	126,675	947,381
Arich Enterprise Co., Ltd.	66,603	66,603	1,155,680

Note 1: Investments in Mainland China are differentiated by the following four methods:

- (1) Direct investment in Mainland China with remittance through a third region.
- (2) Indirect investment in Mainland China through an existing investee company in a third region.
- (3) Other methods (i.e. entrusted Investment)

Note 2: Recognition of investment gain or loss during current period is pursuant to the following:

- (1) If the corporation is in the set-up phase, notes are required.
- (2) Recognition basis of investment gains or losses is determined by the following three types, and related notes are required.
 - 1) Financial statements of the investee company were audited and certified by an international firm in cooperation with an R.O.C. accounting firm.
 - 2) Financial statements of the investee company were audited and certified by the external accountant of the parent company.
 - 3) Others

Note 3: The liquidation procedure of Excelsior Healthcare (Shanghai) Corporation was completed in March 2016, and the investment had remitted to Excelsior Healthcare Co., Limited in the third place. As of March 31, 2026, the accumulated amount of investment from Taiwan has not been repatriated yet.

Note 4: The disposal of Shanghai Lintech Medicare Co. was completed in December 2015. As of March 31, 2026, the original investment amount of \$29,213 thousand from Taiwan has not been repatriated yet.

Note 5: The current investment outflow is not included the direct investment amount of \$207,380 thousand through the third region.

Note 6: The liquidation, with the deductible amount of USD 826 thousand, had been completed in November 2018, and the Investment Commission's authorization letter was obtained on April 10, 2025.

Note 7: Based on a resolution approved during its board meeting held on December 18, 2024, Sino Excelsior Investment Inc. conducted a cash capital reduction of CNY25,000 thousand, at a ratio of 42% with the approval of the competent authority on February 6, 2025. The fund had been remitted to Excelsior Medical (HK) Co., Ltd., belonging to a third region. As of December 31, 2025, the accumulated amount of investment from Taiwan has not yet to be repatriated.

Note 8: (1)The upper limit on investment of the Company and Dynamic is the 60% of net value.

(2)The upper limit on investment of Arich is the higher of \$80,000 thousand or 60% of net value.

Note 9: All amounts listed are disclosed in NTD.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Significant transactions :

The significant inter-company transactions with the subsidiary in Mainland China, which were eliminated in the preparation of consolidated financial statements, are disclosed in “Information of significant transactions”.

(14) Segment Information

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of company. Specifically, the Group’s reportable segments were as follows:

- (a) Excelsior segment - the Company.
- (b) Dynamic segment - Dynamic, Hong Kong Dynamic, Excelsior Beauty, Guangzhou Dynamic, and CYJ International Taiwan Inc..
- (c) Arich segment - Arich , and Arich Best Chain.
- (d) Other segment - Bestsmile, Excelsior Healthcare, EG Healthcare, Excelsior Investment (Malaysia), Renal Laboratories Sdn. Bhd., Medi-Chem Systems Sdn. Bhd., Renal Management Sdn. Bhd., Excelsior Asset, Hong Kong Excelsior and SinoExcelsior Investment.

The Group’s operating segment information and reconciliation are as follows:

<u>For the Three Months Ended March 31, 2026</u>	<u>Excelsiro segment</u>	<u>Dynamic segment</u>	<u>Arich segment</u>	<u>Others</u>	<u>Adjustment and Elimination</u>	<u>Total</u>
Revenue						
Revenue from external customers	\$ 1,377,427	340,657	411,381	213,493	-	2,342,958
Inter-segment revenue	59,400	2,119	-	33,160	(94,679)	-
Total	\$ 1,436,827	342,776	411,381	246,653	(94,679)	2,342,958
Reportable segment profit (loss)	\$ 240,026	44,462	23,264	109,594	(123,410)	293,936
For the Three Months Ended March 31, 2025						
Revenue						
Revenue from external customers	\$ 1,269,334	351,078	393,801	135,112	-	2,149,325
Inter-segment revenue	37,407	157	-	12,442	(50,006)	-
Total	\$ 1,306,741	351,235	393,801	147,554	(50,006)	2,149,325
Reportable segment profit (loss)	\$ 226,667	58,373	35,590	88,700	(112,059)	297,271